Document and Entity Information
Document and Entity Information | 6 Months Ended |
Jun. 30, 2023 | |
Document Information [Line Items] | |
Document Type | 6-K |
Amendment Flag | false |
Document Period End Date | Jun. 30, 2023 |
Document Fiscal Year Focus | 2023 |
Document Fiscal Period Focus | Q2 |
Entity Registrant Name | Novartis AG |
Entity Central Index Key | 0001114448 |
Current Fiscal Year End Date | --12-31 |
Consolidated income statements
Consolidated income statements - USD ($) shares in Millions, $ in Millions | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | ||
Statement [line items] | |||||
Net sales | $ 13,622 | $ 12,781 | $ 26,575 | $ 25,312 | |
Other revenues | 314 | 304 | 569 | 587 | |
Cost of goods sold | (4,341) | (3,751) | (8,272) | (7,607) | |
Gross profit | 9,595 | 9,334 | 18,872 | 18,292 | |
Selling, general and administration | (3,686) | (3,581) | (7,129) | (7,093) | |
Research and development | (2,526) | (2,498) | (5,320) | (4,818) | |
Other income | 147 | 303 | 1,117 | 529 | |
Other expense | (610) | (1,330) | (1,764) | (1,830) | |
Operating income | 2,920 | 2,228 | 5,776 | 5,080 | |
Loss from associated companies | (2) | (3) | (2) | ||
Interest expense | (224) | (202) | (435) | (403) | |
Other financial income and expense | 75 | 16 | 171 | 36 | |
Income before taxes | 2,769 | 2,042 | 5,509 | 4,711 | |
Income taxes | (452) | (347) | (898) | (797) | |
Net income | 2,317 | 1,695 | 4,611 | 3,914 | |
Attributable to | |||||
Shareholders of Novartis AG | 2,316 | 1,694 | 4,609 | 3,916 | |
Non-controlling interests | $ 1 | $ 1 | $ 2 | $ (2) | |
Basic earnings per share [abstract] | |||||
Weighted average number of ordinary shares outstanding | 2,083 | 2,198 | 2,097 | 2,211 | |
Basic earnings per share | [1] | $ 1.11 | $ 0.77 | $ 2.20 | $ 1.77 |
Diluted earnings per share [abstract] | |||||
Adjusted weighted average number of ordinary shares outstanding | 2,095 | 2,211 | 2,109 | 2,224 | |
Diluted earnings per share | [1] | $ 1.11 | $ 0.77 | $ 2.19 | $ 1.76 |
[1]Earnings per share (EPS) is calculated on the amount of net income attributable to shareholders of Novartis AG. |
Consolidated statements of comp
Consolidated statements of comprehensive income - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Statement [line items] | ||||
Net income | $ 2,317 | $ 1,695 | $ 4,611 | $ 3,914 |
Other comprehensive income to be eventually recycled into the consolidated income statement | ||||
Net investment hedge | 6 | 95 | (29) | 120 |
Currency translation effects | 216 | (1,014) | 522 | (1,284) |
Total of items to eventually recycle | 222 | (919) | 493 | (1,164) |
Other comprehensive income never to be recycled into the consolidated income statement | ||||
Actuarial (losses)/gains from defined benefit plans, net of taxes | (1) | 475 | (59) | 2,342 |
Fair value adjustments on equity securities, net of taxes | (2) | (145) | (46) | (325) |
Total of items never to be recycled | (3) | 330 | (105) | 2,017 |
Total comprehensive income | 2,536 | 1,106 | 4,999 | 4,767 |
Attributable to | ||||
Shareholders of Novartis AG | 2,535 | 1,109 | 4,996 | 4,773 |
Comprehensive income, attributable to non-controlling interests | $ 1 | $ (3) | $ 3 | $ (6) |
Consolidated balance sheets
Consolidated balance sheets - USD ($) $ in Millions | Jun. 30, 2023 | Dec. 31, 2022 |
Non-current assets [abstract] | ||
Property, plant and equipment | $ 10,825 | $ 10,764 |
Right-of-use assets | 1,452 | 1,431 |
Goodwill | 29,522 | 29,301 |
Intangible assets other than goodwill | 28,003 | 31,644 |
Investment in associated companies | 127 | 143 |
Deferred tax assets | 4,043 | 3,739 |
Financial assets | 2,306 | 2,411 |
Other non-current assets | 1,208 | 1,110 |
Total non-current assets | 77,486 | 80,543 |
Current assets [abstract] | ||
Inventories | 8,228 | 7,175 |
Current trade receivables | 9,195 | 8,066 |
Income tax receivable | 348 | 268 |
Marketable securities, commodities, time deposits and derivative financial instruments | 289 | 11,413 |
Cash and cash equivalents | 10,885 | 7,517 |
Other current assets | 2,828 | 2,471 |
Total current assets without disposal group | 31,773 | 36,910 |
Assets held for sale | 1,720 | |
Total current assets | 33,493 | 36,910 |
Total assets | 110,979 | 117,453 |
Equity [abstract] | ||
Share capital | 842 | 890 |
Treasury shares | (52) | (92) |
Reserves | 51,057 | 58,544 |
Equity attributable to Novartis AG shareholders | 51,847 | 59,342 |
Non-controlling interests | 84 | 81 |
Total equity | 51,931 | 59,423 |
Non-current liabilities [abstract] | ||
Financial debts | 18,259 | 20,244 |
Lease liabilities | 1,545 | 1,538 |
Deferred tax liabilities | 2,526 | 2,686 |
Provisions and other non-current liabilities | 4,809 | 4,906 |
Total non-current liabilities | 27,139 | 29,374 |
Current liabilities [abstract] | ||
Trade payables | 5,350 | 5,146 |
Financial debts and derivative financial instruments | 8,289 | 5,931 |
Lease liabilities | 247 | 251 |
Current income tax liabilities | 2,651 | 2,533 |
Provisions and other current liabilities | 15,338 | 14,795 |
Total current liabilities without disposal group | 31,875 | 28,656 |
Liabilities held for sale | 34 | |
Total current liabilities | 31,909 | 28,656 |
Total liabilities | 59,048 | 58,030 |
Total equity and liabilities | $ 110,979 | $ 117,453 |
Consolidated statements of chan
Consolidated statements of changes in equity - USD ($) $ in Millions | Total | Equity attributable to owners of parent [member] | Share capital | Treasury shares | Retained earnings | Total value adjustments | Non-controlling interests [member] |
Equity | $ 67,822 | $ 67,655 | $ 901 | $ (48) | $ 70,989 | $ (4,187) | $ 167 |
Equity at beginning of period at Dec. 31, 2021 | 67,822 | 67,655 | 901 | (48) | 70,989 | (4,187) | 167 |
Net income | 3,914 | 3,916 | 3,916 | (2) | |||
Other comprehensive income | 853 | 857 | 857 | (4) | |||
Total comprehensive income | 4,767 | 4,773 | 3,916 | 857 | (6) | ||
Dividends | (7,506) | (7,506) | (7,506) | ||||
Purchase of treasury shares | (5,490) | (5,490) | (33) | (5,457) | |||
Reduction of share capital | (11) | 15 | (4) | ||||
Exercise of options and employee transactions, equity impact | 91 | 91 | 1 | 90 | |||
Equity-based compensation | 437 | 437 | 5 | 432 | |||
Shares delivered to divested business employees, equity impact | 5 | 5 | 0 | 5 | |||
Taxes on treasury shares | 11 | 11 | 11 | ||||
(Increase)/decrease of treasury share repurchase obligation under a share buyback trading plan | 2,809 | 2,809 | 2,809 | ||||
Fair value adjustments on equity securities sold, reclassified to retained earnings | 7 | (7) | |||||
Changes in non-controlling interests | (80) | (80) | |||||
Other movements | 140 | 140 | 140 | ||||
Total of other equity movements | (9,583) | (9,503) | (11) | (12) | (9,473) | (7) | (80) |
Equity at end of period at Jun. 30, 2022 | 63,006 | 62,925 | 890 | (60) | 65,432 | (3,337) | 81 |
Equity | 61,704 | 61,540 | 901 | (60) | 63,451 | (2,752) | 164 |
Equity at beginning of period at Mar. 31, 2022 | 61,704 | 61,540 | 901 | (60) | 63,451 | (2,752) | 164 |
Net income | 1,695 | 1,694 | 1,694 | 1 | |||
Other comprehensive income | (589) | (585) | (585) | (4) | |||
Total comprehensive income | 1,106 | 1,109 | 1,694 | (585) | (3) | ||
Purchase of treasury shares | (2,683) | (2,683) | (16) | (2,667) | |||
Reduction of share capital | (11) | 15 | (4) | ||||
Exercise of options and employee transactions, equity impact | (2) | (2) | (2) | ||||
Equity-based compensation | 204 | 204 | 1 | 203 | |||
Taxes on treasury shares | 1 | 1 | 1 | ||||
(Increase)/decrease of treasury share repurchase obligation under a share buyback trading plan | 2,639 | 2,639 | 2,639 | ||||
Changes in non-controlling interests | (80) | (80) | |||||
Other movements | 117 | 117 | 117 | ||||
Total of other equity movements | 196 | 276 | (11) | 287 | (80) | ||
Equity at end of period at Jun. 30, 2022 | 63,006 | 62,925 | 890 | (60) | 65,432 | (3,337) | 81 |
Equity | 63,006 | 62,925 | 890 | (60) | 65,432 | (3,337) | 81 |
Equity | 59,423 | 59,342 | 890 | (92) | 63,540 | (4,996) | 81 |
Equity at beginning of period at Dec. 31, 2022 | 59,423 | 59,342 | 890 | (92) | 63,540 | (4,996) | 81 |
Net income | 4,611 | 4,609 | 4,609 | 2 | |||
Other comprehensive income | 388 | 387 | 387 | 1 | |||
Total comprehensive income | 4,999 | 4,996 | 4,609 | 387 | 3 | ||
Dividends | (7,255) | (7,255) | (7,255) | ||||
Purchase of treasury shares | (5,888) | (5,888) | (35) | (5,853) | |||
Reduction of share capital | (48) | 68 | (20) | ||||
Exercise of options and employee transactions, equity impact | 153 | 153 | 2 | 151 | |||
Equity-based compensation | 433 | 433 | 5 | 428 | |||
Taxes on treasury shares | 8 | 8 | 8 | ||||
Fair value adjustments on equity securities sold, reclassified to retained earnings | 16 | (16) | |||||
Other movements | 58 | 58 | 58 | ||||
Total of other equity movements | (12,491) | (12,491) | (48) | 40 | (12,467) | (16) | |
Equity at end of period at Jun. 30, 2023 | 51,931 | 51,847 | 842 | (52) | 55,682 | (4,625) | 84 |
Equity | 52,142 | 52,059 | 842 | (36) | 56,089 | (4,836) | 83 |
Equity at beginning of period at Mar. 31, 2023 | 52,142 | 52,059 | 842 | (36) | 56,089 | (4,836) | 83 |
Net income | 2,317 | 2,316 | 2,316 | 1 | |||
Other comprehensive income | 219 | 219 | 219 | 0 | |||
Total comprehensive income | 2,536 | 2,535 | 2,316 | 219 | 1 | ||
Purchase of treasury shares | (3,011) | (3,011) | (17) | (2,994) | |||
Equity-based compensation | 242 | 242 | 1 | 241 | |||
Fair value adjustments on equity securities sold, reclassified to retained earnings | 8 | (8) | |||||
Other movements | 22 | 22 | 22 | ||||
Total of other equity movements | (2,747) | (2,747) | (16) | (2,723) | (8) | ||
Equity at end of period at Jun. 30, 2023 | 51,931 | 51,847 | 842 | (52) | 55,682 | (4,625) | 84 |
Equity | $ 51,931 | $ 51,847 | $ 842 | $ (52) | $ 55,682 | $ (4,625) | $ 84 |
Consolidated cash flow statemen
Consolidated cash flow statements - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Statement [line items] | ||||
Net income | $ 2,317 | $ 1,695 | $ 4,611 | $ 3,914 |
Reversal of non-cash items and other adjustments | 2,883 | 3,061 | 5,890 | 5,414 |
Dividends received from associated companies and others | 1 | 5 | 1 | |
Interest received | 118 | 21 | 374 | 38 |
Interest paid | (230) | (198) | (353) | (308) |
Other financial receipts | (53) | 27 | ||
Other financial payments | (5) | (13) | (11) | (43) |
Income taxes paid | (1,030) | (606) | (1,378) | (1,239) |
Net cash flows from operating activities before working capital and provision changes | 4,000 | 3,961 | 9,165 | 7,777 |
Payments out of provisions and other net cash movements in non-current liabilities | (262) | (152) | (966) | (308) |
Change in net current assets and other operating cash flow items | (162) | (54) | (1,666) | (2,065) |
Net cash flows from operating activities | 3,576 | 3,755 | 6,533 | 5,404 |
Purchases of property, plant and equipment | (301) | (257) | (538) | (514) |
Proceeds from sale of property, plant and equipment | 7 | 13 | 39 | 46 |
Purchases of intangible assets | (695) | (326) | (928) | (928) |
Proceeds from sale of intangible assets | 3 | 127 | 133 | 193 |
Purchases of financial assets | (27) | (38) | (69) | (73) |
Proceeds from sale of financial assets | 47 | 30 | 111 | 96 |
Acquisitions and divestments of interests in associated companies, net | (2) | (2) | (5) | (20) |
Acquisitions and divestments of businesses, net | (84) | (59) | (123) | (880) |
Purchases of marketable securities, commodities and time deposits | (4) | (13,233) | (69) | (17,454) |
Proceeds from sale of marketable securities, commodities and time deposits | 3 | 2,117 | 11,017 | 17,271 |
Net cash flows from/(used in) investing activities | (1,053) | (11,628) | 9,568 | (2,263) |
Dividends paid to shareholders of Novartis AG | (7,255) | (7,506) | ||
Purchases of treasury shares | (2,957) | (2,714) | (5,843) | (5,256) |
Proceeds from exercised options and other treasury share transactions, net | 6 | 159 | 100 | |
Increase in non-current financial debts | 4 | 3 | 6 | 6 |
Repayments of the current portion of non-current financial debts | (1,075) | (1,075) | ||
Change in current financial debts | (713) | 1,477 | 309 | 1,955 |
Payments of lease liabilities | (73) | (74) | (148) | (151) |
Other financing cash flows, net | 102 | 75 | (67) | 97 |
Net cash flows used in financing activities | (3,637) | (2,302) | (12,839) | (11,830) |
Net change in cash and cash equivalents before effect of exchange rate changes | (1,114) | (10,175) | 3,262 | (8,689) |
Effect of exchange rate changes on cash and cash equivalents | (1) | (52) | 106 | (93) |
Net change in cash and cash equivalents | (1,115) | (10,227) | 3,368 | (8,782) |
Cash and cash equivalents at beginning of period | 12,000 | 13,852 | 7,517 | 12,407 |
Cash and cash equivalents at end of period | $ 10,885 | $ 3,625 | $ 10,885 | $ 3,625 |
Basis of preparation
Basis of preparation | 6 Months Ended |
Jun. 30, 2023 | |
Basis of preparation [abstract] | |
Disclosure of basis of preparation of financial statements [text block] | 1. Basis of preparation These Condensed Interim Consolidated Financial Statements for the three-month and six-month interim period ended June 30, 2023, were prepared in accordance with International Accounting Standard 34 Interim Financial Reporting |
Selected critical accounting po
Selected critical accounting policies | 6 Months Ended |
Jun. 30, 2023 | |
Selected critical accounting policies [abstract] | |
Disclosure of significant accounting policies [text block] | 2. Selected critical accounting policies The Group’s principal accounting policies are set out in Note 1 to the Consolidated Financial Statements in the 2022 Annual Report and conform with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board. The preparation of interim financial statements requires management to make certain estimates and assumptions, either at the balance sheet date or during the period, which affect the reported amounts of revenues, expenses, assets, liabilities and contingent amounts. Estimates are based on historical experience and other assumptions that are considered reasonable under the given circumstances and are regularly monitored. Actual outcomes and results could differ from those estimates and assumptions. Revisions to estimates are recognized in the period in which the estimate is revised. As disclosed in the 2022 Annual Report, goodwill, and acquired In-Process Research & Development projects are reviewed for impairment at least annually and these, as well as all other investments in intangible assets, are reviewed for impairment whenever an event or decision occurs that raises concern about their balance sheet carrying value. The amount of goodwill and other intangible assets on the Group’s consolidated balance sheet has risen significantly in recent years, primarily from acquisitions. Impairment testing may lead to potentially significant impairment charges in the future that could have a materially adverse impact on the Group’s results of operations and financial condition. The Group’s activities are not subject to significant seasonal fluctuations. |
Significant transactions
Significant transactions | 6 Months Ended |
Jun. 30, 2023 | |
Disclosure of significant transactions [abstract] | |
Disclosure of Significant transactions [text block] | 3. Significant transactions The Group applied the acquisition method of accounting for businesses acquired, and did not elect to apply the optional concentration test to account for acquired business as an asset separately acquired. Significant pending transactions entered into in second quarter 2023 and closed in July 2023 Innovative Medicines – acquisition of DTx Pharma Inc. In the second quarter of 2023, Novartis entered into an agreement to acquire DTx Pharma Inc. (DTx), a San-Diego US based, pre-clinical stage biotechnology company focused on leveraging its proprietary FALCON platform to develop siRNA therapies for neuroscience indications. DTx’s lead program, DTx-1252 targets the root cause of CMT1A—the overexpression of PMP22, a protein that causes the myelin sheath that supports and insulates nerves in the peripheral nervous system to function abnormally. The transaction also includes two additional pre-clinical programs for other neuroscience indications. The transaction closed on July 14, 2023. The purchase price consists of a cash payment of USD 0.5 billion and potential additional milestones up to USD 0.5 billion, which the DTx Pharma Inc. shareholders are eligible to receive upon achievement of specified milestone. Significant pending transaction in 2023 Innovative Medicines – acquisition of Chinook Therapeutics On June 12, 2023, Novartis entered into an agreement to acquire Chinook Therapeutics, a Seattle, WA, based clinical stage biopharmaceutical company with two late-stage medicines in development for rare, severe chronic kidney diseases. The purchase price will consist of a cash payment of USD 3.2 billion and potential additional payments of up to USD 0.3 billion, which Chinook Therapeutics shareholders are eligible to receive upon achievement of specified milestones. The transaction is expected to be completed in the second half of 2023, subject to customary closing conditions, including approval of Chinook Therapeutics shareholders and receipt of regulatory approvals. Significant transactions in 2022 Innovative Medicines – acquisition of Gyroscope Therapeutics Holdings plc On December 22, 2021, Novartis entered into an agreement to acquire all outstanding shares of Gyroscope Therapeutics Holdings plc (Gyroscope), a UK-based ocular gene therapy company. Gyroscope focuses on the discovery and development of gene therapy treatments for retinal indications. The purchase price consisted of a cash payment of USD 0.8 0.7 The fair value of the total purchase consideration was USD 1.0 billion. The amount consisted of an upfront cash payment of USD 0.8 billion (including customary purchase price adjustments) and the fair value of contingent consideration of USD 0.2 billion, which Gyroscope shareholders are eligible to receive upon achievement of specified milestones. The purchase price allocation resulted in net identifiable assets of USD 0.9 billion, consisting primarily of intangible assets of USD 1.1 billion and net deferred tax liabilities of USD 0.2 billion. Goodwill amounted to USD 0.1 billion. The 2022 results of operations since the date of acquisition were not material. |
Summary of equity attributable
Summary of equity attributable to Novartis AG shareholders | 6 Months Ended |
Jun. 30, 2023 | |
Disclosure of equity [abstract] | |
Disclosure of equity [text block] | 4. Summary of equity attributable to Novartis AG shareholders Number of outstanding shares (in millions) Issued share capital and reserves attributable to Novartis AG shareholders (in USD millions) Note 2023 2022 H1 2023 H1 2022 Balance at beginning of year 2 119.6 2 234.9 59 342 67 655 Shares acquired to be canceled -61.3 -61.7 -5 767 -5 381 Other share purchases -1.3 -1.2 -121 -109 Exercise of options and employee transactions 4.1 2.8 1.9 153 91 Equity-based compensation 8.5 8.9 433 437 Shares delivered to Alcon employees as a result of the Alcon spin-off 0.0 5 Taxes on treasury share transactions 8 11 Decrease of treasury share repurchase obligation Dividends -7 255 -7 506 Net income of the period attributable to shareholders of Novartis AG 4 609 3 916 Other comprehensive income attributable to shareholders of Novartis AG 387 857 Other movements 4.3 58 140 Balance at June 30 2 068.3 2 182.8 51 847 62 925 4.1. At December 31, 2022, the market maker held 3 million (December 31, 2021: 3 million) written call options, originally issued as part of the share-based compensation for employees, that had not yet been exercised. The weighted average exercise price of these options at December 31, 2022, was USD 66.07 (December 31, 2021: USD 61.45), and they had contractual lives of 10 years, with remaining lives less than one year (December 31, 2021: two years). In the first quarter of 2023, the market maker exercised 3 million written call options and as a result there are no written call option outstanding at June 30, 2023. 4.2. In December 2021, Novartis entered into an irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares on the second trading line under its up-to USD 15.0 billion share buyback. The arrangement was updated in July 2022, December 2022, and May 2023, and concluded in June 2023. In addition, in June 2023, Novartis entered into a new irrevocable, non-discretionary arrangement with a bank to repurchase 11.7 million Novartis shares on the second trading line. Novartis is able to cancel this arrangement but would be subject to a 90-day waiting period under certain conditions. As of June 30, 2023, these waiting period conditions were not applicable and as a result, there was no requirement to record a liability under this arrangement as of June 30, 2023. 4.3. Other movements include, for subsidiaries in hyperinflationary economies, the impact of the restatement of the equity balances of the current period as well as restatement of the non-monetary assets and liabilities with the general price index at the beginning of the period. |
Financial instruments
Financial instruments | 6 Months Ended |
Jun. 30, 2023 | |
Financial Instruments - additional disclosure [abstract] | |
Disclosure of detailed information about financial instruments [text block] | 5. Financial instruments Fair value by hierarchy The following table illustrates the three hierarchical levels for valuing financial instruments at fair value as of June 30, 2023, and December 31, 2022. For additional information on the hierarchies and other matters, please refer to the Consolidated Financial Statements in the 2022 Annual Report, published on February 1, 2023. Level 1 Level 2 Level 3 Total Jun 30, Dec 31, Jun 30, Dec 31, Jun 30, Dec 31, Jun 30, Dec 31, Financial assets Cash and cash equivalents Debt securities 49 49 Total cash and cash equivalents at fair value 49 49 Marketable securities Debt securities 8 9 8 9 Derivative financial instruments 102 204 102 204 Total marketable securities and derivative financial instruments at fair value 110 213 110 213 Current contingent consideration receivables 58 43 58 43 Long-term financial investments Debt and equity securities 488 473 11 10 599 699 1 098 1 182 Fund investments 7 20 194 261 201 281 Non-current contingent consideration receivables 675 607 675 607 Total long-term financial investments at fair value 495 493 11 10 1 468 1 567 1 974 2 070 Associated companies at fair value through profit or loss 114 129 114 129 Financial liabilities Current contingent consideration liabilities -29 -131 -29 -131 Current other financial liabilities -189 -189 Derivative financial instruments -40 -55 -40 -55 Total current financial liabilities at fair value -40 -55 -218 -131 -258 -186 Non-current contingent consideration liabilities -593 -704 -593 -704 Non-current other financial liabilities -232 -232 Total non-current financial liabilities at fair value -593 -936 -593 -936 In the first half of 2023, there were three transfers of equity securities from Level 3 to Level 1 for USD 63 million mainly due to Initial Public Offering. The fair value of straight bonds amounted to USD 20.7 billion at June 30, 2023 (USD 20.3 billion at December 31, 2022) compared with the carrying amount of USD 22.5 billion at June 30, 2023 (USD 22.3 billion at December 31, 2022). For all other financial assets and liabilities, the carrying amount is a reasonable approximation of the fair value. The carrying amount of financial assets included in the line total long-term financial investments of USD 2.0 billion at June 30, 2023 (USD 2.1 billion at December 31, 2022) is included in the line “Financial assets” of the consolidated balance sheets. The carrying amount of non-current contingent consideration liabilities and non-current other financial liabilities included in the line total non-current financial liabilities at fair value of USD 0.6 billion at June 30, 2023 (USD 0.9 billion at December 31, 2022) is included in the line “Provisions and other non-current liabilities” of the consolidated balance sheet. The Group’s exposure to financial risks has not changed significantly during the period and there have been no major changes to the risk management department or in any risk management policies. |
Details to the consolidated sta
Details to the consolidated statements of cash flows | 6 Months Ended |
Jun. 30, 2023 | |
Disclosure of details to the consolidated statements of cash flows [abstract] | |
Disclosure of cash flow statement [text block] | 6. Details to the consolidated statements of cash flows 6.1. Non-cash items and other adjustments The following table shows the reversal of non-cash items and other adjustments in the consolidated statements of cash flows. (USD millions) Q2 2023 Q2 2022 Depreciation, amortization and impairments on: Property, plant and equipment 262 507 Right-of-use assets 77 76 Intangible assets 1 486 1 219 Financial assets 1 28 97 Change in provisions and other non-current liabilities 73 547 Losses/(gains) on disposal and other adjustments on property, plant and equipment; intangible assets; -114 Equity-settled compensation expense 233 204 Loss from associated companies 2 Income taxes 452 347 Net financial expense 149 186 Other 36 -8 Total 2 883 3 061 1 (USD millions) H1 2023 H1 2022 Depreciation, amortization and impairments on: Property, plant and equipment 565 821 Right-of-use assets 151 154 Intangible assets 3 105 2 232 Financial assets 1 75 199 Change in provisions and other non-current liabilities 585 635 Gains on disposal and other adjustments on property, plant and equipment; intangible assets; -217 -192 Equity-settled compensation expense 432 407 Loss from associated companies 3 2 Income taxes 898 797 Net financial expense 264 367 Other 29 -8 Total 5 890 5 414 1 In the second quarter of 2023, there were no additions to intangible assets (Q2 2022: nil; other than through business combinations) with deferred payments. In the second quarter of 2023, there were USD 74 million (Q2 2022: USD 79 million) additions to right-of-use assets recognized. In the first half of 2023, there were no additions to intangible assets with deferred payments. In the first half of 2022, other than through business combinations, there were USD 0.3 billion additions to intangible assets with deferred payments. In the first half of 2023, there were USD 225 million (H1 2022: USD 122 million) additions to right-of-use assets recognized. 6.2. Cash flows from changes in working capital and other operating items included in the net cash flows from operating activities (USD millions) Q2 2023 Q2 2022 H1 2023 H1 2022 Increase in inventories -376 -194 -996 -619 Increase in trade receivables -425 -413 -1 275 -909 Increase/(decrease) in trade payables 127 11 214 -132 Change in other current and non-current assets -111 70 -288 -293 Change in other current liabilities 623 472 679 -112 Total -162 -54 -1 666 -2 065 6.3. Cash flows arising from acquisitions and divestments of businesses, net The following table is a summary of the cash flow impact of acquisitions and divestments of businesses. The most significant transactions are described in Note 3. (USD millions) Q2 2023 Q2 2022 H1 2023 H1 2022 Net assets recognized as a result of acquisitions of businesses 0 -107 0 -1 086 Fair value of previously held equity interests 24 24 Contingent consideration payable, net 31 -26 212 Payments (incl. prepayments), deferred consideration and other adjustments, net -100 12 -100 -13 Cash flows used for acquisitions of businesses -100 -40 -126 -863 Cash flows from/(used for) divestments of businesses, net 1 16 -19 3 -17 Cash flows used for acquisitions and divestments of businesses, net -84 -59 -123 -880 1 In the first half of 2023, USD 3 million (Q2 2023: USD 16 million) represented the net cash inflows from divestments in prior years. In the first half of 2022, USD 17 million (Q2 2022: USD 19 million) net cash outflows from divestments of businesses included USD 20 million (Q2 2022: USD 20 million) reduction to cash and cash equivalents due to the derecognized cash and cash equivalents following a loss of control of a company upon expiry of an option to purchase the company, partly offset by net cash inflows of USD 3 million (Q2 2022: USD 1 million) from business divestments in the 2022 periods and in prior years. In the first half of 2022, the net identifiable assets of divested businesses amounted to USD 140 million (Q2 2022: USD 106 million), comprised of non-current assets of USD 118 million (Q2 2022: USD 113 million), current assets of USD 65 million (Q2 2022: USD 36 million), including USD 29 million (Q2 2022: USD 20 million) cash and cash equivalents and of non-current and current liabilities of USD 43 million (Q2 2022: USD 43 million). The deferred sale price receivable and other adjustments amounted to USD 25 million (Q2 2022: nil). Notes 3 and 7 provide further information regarding acquisitions and divestments of businesses. All acquisitions were for cash. |
Acquisition of businesses
Acquisition of businesses | 6 Months Ended |
Jun. 30, 2023 | |
Disclosure of acquisition of businesses [abstract] | |
Disclosure of business combinations [text block] | 7. Acquisitions of businesses Fair value of assets and liabilities arising from acquisitions of businesses: (USD millions) H1 2023 H1 2022 Property, plant and equipment 13 Right-of-use assets 12 Acquired research and development 1 223 Deferred tax assets 53 Other current assets 5 Cash and cash equivalents 89 Deferred tax liabilities -303 Current and non-current lease liabilities -12 Trade payables and other liabilities -68 Net identifiable assets acquired 0 1 012 Acquired cash and cash equivalents -89 Goodwill 163 Net assets recognized as a result of acquisitions of businesses 0 1 086 Note 3 details significant acquisitions of businesses. There were no significant acquisitions of businesses in the first half of 2023. In the first half of 2022, there was the acquisition of Gyroscope. The goodwill arising out of the Gyroscope acquisition was mainly attributable to the accounting for deferred tax liabilities on acquired assets and the assembled workforce. None of the goodwill arisen in the first half of 2022 was tax deductible. |
Legal proceedings update
Legal proceedings update | 6 Months Ended |
Jun. 30, 2023 | |
Legal proceedings update [abstract] | |
Legal proceedings update [text block] | 8. Legal proceedings update A number of Novartis companies are, and will likely continue to be, subject to various legal proceedings, including litigations, arbitrations and governmental investigations, that arise from time to time. Legal proceedings are inherently unpredictable. As a result, the Group may become subject to substantial liabilities that may not be covered by insurance and may in the future incur judgments or enter into settlements of claims that could have a material adverse effect on its results of operations or cash flow. Note 20 to the Consolidated Financial Statements in our 2022 Annual Report and 2022 Form 20-F contains a summary as of the date of these reports of significant legal proceedings to which Novartis or its subsidiaries were a party. The following is a summary as of July 17, 2023, of significant developments in those proceedings, as well as any new significant proceedings commenced since the date of the 2022 Annual Report and 2022 Form 20-F. Investigations and related litigations Government generic pricing antitrust investigations, antitrust class actions Since 2016, Sandoz Inc. has been part of an investigation into alleged price fixing and market allocation of generic drugs in the United States. In 2020, Sandoz Inc. reached a resolution with the DOJ Antitrust Division, pursuant to which Sandoz Inc. paid USD 195 million and entered into a deferred prosecution agreement (DPA). The Sandoz Inc. resolution related to instances of misconduct at the Company between 2013 and 2015 with regard to certain generic drugs sold in the United States. The term of the DPA concluded in March 2023 and the underlying matter has been dismissed. Sandoz Inc. also finalized a resolution with the DOJ Civil Division and in 2021 paid USD 185 million to settle related claims arising under the False Claims Acts (FCA), and entered into a corporate integrity agreement with the Office of Inspector General (OIG) of the US Department of Health and Human Services (HHS). This resolved all federal government matters related to price fixing allegations. Since the third quarter of 2016, Sandoz Inc. and Fougera Pharmaceuticals Inc. have been sued alongside other generic pharmaceutical companies in numerous related individual and putative class action complaints by direct and indirect private purchasers and by over 50 US states and territories, represented by their respective Attorneys General. Plaintiffs claim that defendants, including Sandoz Inc., engaged in price fixing and market allocation of generic drugs in the United States, and seek damages and injunctive relief. The litigation includes complaints alleging product-specific conspiracies, as well as complaints alleging the existence of an overarching industry conspiracy, and assert claims for damages and penalties under federal and state antitrust and consumer protection acts. The cases have been consolidated for pretrial purposes in the United States District Court (USDC) for the Eastern District of Pennsylvania, and the claims are being vigorously contested. Lucentis/Avastin® matters In connection with an investigation into whether Novartis entities, F. Hoffmann-La Roche AG, Genentech Inc. and Roche S.p.A. colluded to artificially preserve the market positions of Avastin® and Lucentis, in 2014 the Italian Competition Authority (ICA) imposed a fine equivalent to USD 125 million on the Novartis entities. Novartis paid the fine, subject to the right to later claim recoupment, and appealed before the Consiglio di Stato (CdS). In 2014 and 2015, the Italian Ministry of Health and the Lombardia region sent letters with payment requests for a total equivalent of approximately USD 1.3 billion in damages from Novartis and Roche entities based on these allegations. In 2019, the CdS upheld the ICA decision and fine. Following that CdS decision, several additional Italian regions and hospitals sent letters claiming damages for an aggregate amount of approximately USD 330 million. Novartis filed a revocation action before the CdS in 2019 and a further appeal before the Supreme Court in 2020. Respectively in October 2021 and May 2023, the Supreme Court and the CdS rejected Novartis’s actions. The ICA decision is now final. In 2019, the French Competition Authority (FCA) issued a Statement of Objections against Novartis entities, alleging anti-competitive practices on the French market for anti-vascular endothelial growth factor treatments for wet age-related macular degeneration from 2008 to 2013. In 2020, the FCA issued a decision finding that the Novartis entities had infringed competition law by abusing a dominant position and imposing a fine equivalent to approximately USD 452 million. Novartis paid the fine, again subject to recoupment, and appealed the FCA’s decision. In February 2023, the Paris Court of Appeal (Court) overturned the FCA’s decision which triggered the reimbursement of the originally paid fine (recorded as “Other income” in the Company’s consolidated income statement), and in March 2023, the FCA filed an appeal of the Court’s decision. Novartis entities are the subject of similar investigations and proceedings involving competition authorities, which are disclosed in the 2022 Annual Report and 2022 Form 20-F. Antitrust class actions Exforge Since 2018, Novartis Group companies as well as other pharmaceutical companies have been sued by various direct and indirect purchasers of Exforge In addition to the matters described above, there have been other non-material developments in the other legal matters described in Note 20 to the Consolidated Financial Statements contained in our 2022 Annual Report and 2022 Form 20-F. Novartis believes that its total provisions for investigations, product liability, arbitration and other legal matters are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities, there can be no assurance that additional liabilities and costs will not be incurred beyond the amounts provided. |
Segmentation of key figures
Segmentation of key figures | 6 Months Ended |
Jun. 30, 2023 | |
Disclosure of operating segments [abstract] | |
Disclosure of entity's operating segments [text block] | 9. Segmentation of key figures The businesses of Novartis are divided operationally on a worldwide basis into two identified reporting segments: Innovative Medicines and Sandoz. In addition, we separately report Corporate activities. Reporting segments are presented in a manner consistent with the internal reporting to the chief operating decision-maker, which is the Executive Committee of Novartis. The reporting segments are managed separately because they each research, develop, manufacture, distribute and sell distinct products that require differing marketing strategies. The Executive Committee of Novartis is responsible for allocating resources and assessing the performance of the reporting segments. The reporting segments are as follows: Innovative Medicines researches, develops, manufactures, distributes and sells patented pharmaceuticals. The Innovative Medicines Division is organized in two commercial organizational units: Innovative Medicines International and Innovative Medicines US, and is focused on the core therapeutic areas: cardiovascular; immunology; neuroscience; solid tumors and hematology; as well as other promoted brands (in the therapeutic areas of ophthalmology and respiratory) and established brands. Sandoz develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. Effective in the second quarter of 2023, Sandoz is organized globally into two franchises: Generics and Biosimilars. In Generics, Sandoz develops, manufactures and markets finished dosage forms of small molecule pharmaceuticals for sale to third parties across a broad range of therapeutic areas, including finished dosage form of anti-infectives sold to third parties, as well as, active pharmaceutical ingredients and intermediates, mainly antibiotics, for sale to third-party companies. In Biosimilars, Sandoz develops, manufactures and markets protein- or other biotechnology-based products, including biosimilars, and provides biotechnology manufacturing services to other companies. Prior to the second quarter of 2023, Sandoz was organized globally into three business franchises of Retail Generics, Anti-Infectives and Biopharmaceuticals. The change in the second quarter of 2023 combined Retail Generics and Anti-infectives to form Generics, and Biopharmaceuticals was renamed to Biosimilars. Corporate includes the costs of the Group headquarters and those of corporate coordination functions in major countries, and items that are not specific to one segment. Our divisions are supported by Novartis Institutes for BioMedical Research, Global Drug Development, and the Operations unit. Effective January 1, 2023, the Sandoz Division’s biotechnology manufacturing services to other companies’ activities and the Coartem Further details are provided in Note 3 to the Consolidated Financial Statements of the 2022 Annual Report. Segmentation – Consolidated income statements Second quarter Innovative Medicines Sandoz Corporate (including eliminations) 1 Group Q2 2022 2 Q2 2022 2 Q2 2022 2 Net sales to third parties 11 243 10 525 2 379 2 256 13 622 12 781 Sales to other segments 192 178 57 55 -249 -233 Net sales 11 435 10 703 2 436 2 311 -249 -233 13 622 12 781 Other revenues 304 295 6 7 4 2 314 304 Cost of goods sold -3 338 -2 773 -1 250 -1 212 247 234 -4 341 -3 751 Gross profit 8 401 8 225 1 192 1 106 2 3 9 595 9 334 Selling, general and administration -2 955 -2 956 -594 -503 -137 -122 -3 686 -3 581 Research and development -2 304 -2 302 -222 -196 -2 526 -2 498 Other income 108 207 14 23 25 73 147 303 Other expense -251 -968 -178 -73 -181 -289 -610 -1 330 Operating income 2 999 2 206 212 357 -291 -335 2 920 2 228 as % of net sales 26.7% 21.0% 8.9% 15.8% 21.4% 17.4% Loss from associated companies 1 1 -2 -2 -2 Interest expense -224 -202 Other financial income and expense 75 16 Income before taxes 2 769 2 042 Income taxes -452 -347 Net income 2 317 1 695 1 2 Coartem First half Innovative Medicines Sandoz Corporate (including eliminations) 1 Group H1 2022 2 H1 2022 2 H1 2022 2 Net sales to third parties 21 813 20 755 4 762 4 557 26 575 25 312 Sales to other segments 424 388 149 102 -573 -490 Net sales 22 237 21 143 4 911 4 659 -573 -490 26 575 25 312 Other revenues 550 569 12 13 7 5 569 587 Cost of goods sold -6 328 -5 695 -2 517 -2 434 573 522 -8 272 -7 607 Gross profit 16 459 16 017 2 406 2 238 7 37 18 872 18 292 Selling, general and administration -5 715 -5 842 -1 136 -1 016 -278 -235 -7 129 -7 093 Research and development -4 879 -4 414 -441 -404 -5 320 -4 818 Other income 859 352 24 71 234 106 1 117 529 Other expense -1 050 -1 280 -322 -138 -392 -412 -1 764 -1 830 Operating income 5 674 4 833 531 751 -429 -504 5 776 5 080 as % of net sales 26.0% 23.3% 11.2% 16.5% 21.7% 20.1% Loss from associated companies 1 1 1 1 -5 -4 -3 -2 Interest expense -435 -403 Other financial income and expense 171 36 Income before taxes 5 509 4 711 Income taxes -898 -797 Net income 4 611 3 914 1 2 Coartem Segmentation – Additional consolidated balance sheets and income statements disclosure Innovative Medicines Sandoz Corporate (including eliminations) 1 Group Dec 31, Dec 31, Total assets 2 75 633 75 836 16 677 15 752 18 669 25 865 110 979 117 453 Total liabilities -16 942 -16 966 -4 195 -3 710 -37 911 -37 354 -59 048 -58 030 Total equity 51 931 59 423 Net debt 3 15 374 7 245 15 374 7 245 Net operating assets 2 58 691 58 870 12 482 12 042 -3 868 -4 244 67 305 66 668 Included in net operating assets are: Property, plant and equipment 8 463 8 488 1 965 1 861 397 415 10 825 10 764 Goodwill 2 21 992 21 857 7 530 7 444 29 522 29 301 Intangible assets other than goodwill 26 152 29 826 1 427 1 460 424 358 28 003 31 644 1 2 Coartem 3 The following table shows the property, plant and equipment impairment charges and reversals, the right-of-use assets impairment charges, the intangible assets impairment charges and additions to restructuring provisions: Second quarter Innovative Medicines Sandoz Corporate Group (USD millions) Q2 2023 Q2 2022 Q2 2023 Q2 2022 Q2 2023 Q2 2022 Q2 2023 Q2 2022 Property, plant and equipment impairment charges -31 -236 -1 -1 -32 -237 Property, plant and equipment impairment reversals 39 1 2 40 2 Intangible assets impairment charges 1 -453 -226 -2 -4 -455 -230 Additions to restructuring provisions -33 -316 -11 -20 -23 -162 -67 -498 1 The second quarter of 2023 includes an impairment of USD 0.3 billion for the write-down of a currently marketed product to reflect reduction in recoverable amount. First half Innovative Medicines Sandoz Corporate Group (USD millions) H1 2023 H1 2022 H1 2023 H1 2022 H1 2023 H1 2022 H1 2023 H1 2022 Property, plant and equipment impairment charges -58 -258 -2 -1 -1 -60 -260 Property, plant and equipment impairment reversal 48 2 1 3 49 5 Right-of-use assets impaiment charges -1 -1 Intangible assets impairment charges 1 -926 -263 -14 -4 -940 -267 Additions to restructuring provisions -411 -360 -16 -30 -55 -172 -482 -562 1 The first half of 2023 includes an impairment of USD 0.3 billion due to the write-down of IPR&D related to cessation of clinical development program NIZ985 and of USD 0.3 billion for the write-down of a currently marketed product to reflect reduction in recoverable amount. In the first half of 2023, there were no nil nil Pending divestment of intangible assets – Innovative Medicines On June 30, 2023, Novartis entered into an agreement with Bausch + Lomb Corporation to divest the currently marketed product Xiidra As of June 30, 2023, the carrying value of the currently marketed product intangible asset (USD 1.72 billion) and its related contingent consideration liability (USD 34 million) have been reclassified and presented separately as asset and liability held for sale in the Consolidated balance sheet. The amortization of the currently marketed product was ceased as of June 30, 2023. The IPR&D assets to be divested had no carrying value at June 30, 2023. There are no cumulative income or expenses included in other comprehensive income relating to the non-cur- rent asset classified as held for sale. Restructuring provisions movements (USD millions) Q2 2023 Q2 2022 H1 2023 H1 2022 Balance at beginning of period 1 209 331 1 131 345 Additions 67 498 482 562 Cash payments -173 -76 -490 -144 Releases -63 -10 -95 -15 Transfers 1 -1 0 Currency translation effects 4 -11 17 -17 Balance at closing of period 1 045 731 1 045 731 In the first half of 2023, additions to provisions of USD 482 million (Q2: USD 67 million) were mainly related to the continuation of the initiative announced in April 2022, to implement a new streamlined organizational model designed to support innovation, growth and productivity. In the first half of 2022, additions to provisions of USD 562 million (Q2: USD 498 million) were mainly related to the initiative announced in April 2022, to implement a new streamlined organizational model designed to support innovation, growth and productivity, as well as, to the continuation of the Innovative Medicines Division and the Operations unit 2021 restructuring initiatives. Segmentation – Net sales to third parties Net sales by region 1 Second quarter Q2 2022 2 3 Innovative Medicines Europe 3 496 3 481 0 2 31 33 US 4 503 3 967 14 14 40 38 Asia/Africa/Australasia 2 418 2 328 4 10 22 22 Canada and Latin America 826 749 10 19 7 7 Total 11 243 10 525 7 9 100 100 Of which in Established Markets 8 276 7 742 7 7 74 74 Of which in Emerging Growth Markets 2 967 2 783 7 17 26 26 Sandoz Europe 1 329 1 192 11 13 56 53 US 378 411 -8 -8 16 18 Asia/Africa/Australasia 395 406 -3 4 17 18 Canada and Latin America 277 247 12 16 11 11 Total 2 379 2 256 5 8 100 100 Of which in Established Markets 1 685 1 581 7 7 71 70 Of which in Emerging Growth Markets 694 675 3 10 29 30 Group Europe 4 825 4 673 3 5 35 37 US 4 881 4 378 11 11 36 34 Asia/Africa/Australasia 2 813 2 734 3 9 21 21 Canada and Latin America 1 103 996 11 18 8 8 Total 13 622 12 781 7 9 100 100 Of which in Established Markets 9 961 9 323 7 7 73 73 Of which in Emerging Growth Markets 3 661 3 458 6 15 27 27 1 2 Coartem 3 Net sales by region 1 First half H1 2022 2 3 Innovative Medicines Europe 6 917 7 010 -1 2 32 34 US 8 575 7 642 12 12 39 37 Asia/Africa/Australasia 4 717 4 656 1 9 22 22 Canada and Latin America 1 604 1 447 11 19 7 7 Total 21 813 20 755 5 8 100 100 Of which in Established Markets 15 954 15 314 4 6 73 74 Of which in Emerging Growth Markets 5 859 5 441 8 16 27 26 Sandoz Europe 2 695 2 427 11 14 57 53 US 758 819 -7 -7 16 18 Asia/Africa/Australasia 772 811 -5 4 16 18 Canada and Latin America 537 500 7 11 11 11 Total 4 762 4 557 4 8 100 100 Of which in Established Markets 3 330 3 155 6 8 70 69 Of which in Emerging Growth Markets 1 432 1 402 2 8 30 31 Group Europe 9 612 9 437 2 5 36 37 US 9 333 8 461 10 10 35 33 Asia/Africa/Australasia 5 489 5 467 0 8 21 22 Canada and Latin America 2 141 1 947 10 17 8 8 Total 26 575 25 312 5 8 100 100 Of which in Established Markets 19 284 18 469 4 6 73 73 Of which in Emerging Growth Markets 7 291 6 843 7 15 27 27 1 2 Coartem 3 Innovative Medicines Division net sales to third parties by core therapeutic area; other promoted brands; and established brands Second quarter Q2 2023 Q2 2022 % change % change USD m USD m 1 USD cc 2 Cardiovascular Entresto 1 516 1 125 35 37 Leqvio 78 22 255 249 Total Cardiovascular 1 594 1 147 39 41 Immunology Cosentyx 1 272 1 275 0 1 Xolair 3 362 352 3 5 Ilaris 316 275 15 17 Total Immunology 1 950 1 902 3 4 Neuroscience Kesimpta 489 239 105 105 Zolgensma 311 379 -18 -16 Mayzent 94 85 11 11 Aimovig 67 55 22 24 Total Neuroscience 961 758 27 28 Solid Tumors Tafinlar Mekinist 496 452 10 13 Kisqali 493 308 60 66 Pluvicto 240 10 nm nm Lutathera 150 86 74 75 Piqray/Vijoice 130 85 53 54 Votrient 106 124 -15 -13 Tabrecta 41 30 37 37 Total Solid Tumors 1 656 1 095 51 54 Hematology Promacta/Revolade 583 534 9 11 Tasigna 476 498 -4 -3 Jakavi 435 398 9 11 Kymriah 129 136 -5 -5 Scemblix 106 31 242 248 Adakveo 53 49 8 8 Total Hematology 1 782 1 646 8 10 Other Promoted Brands Ultibro 114 126 -10 -8 Xiidra 96 126 -24 -24 Beovu 53 54 -2 0 Other respiratory 23 20 15 22 Total Other Promoted Brands 286 326 -12 -11 Total Promoted Brands 8 229 6 874 20 22 Established Brands Lucentis 395 501 -21 -20 Sandostatin 331 318 4 5 Gilenya 269 555 -52 -52 Exforge 184 199 -8 -4 Galvus 175 222 -21 -15 Diovan 155 159 -3 2 Gleevec/Glivec 142 194 -27 -24 Afinitor/Votubia 116 143 -19 -17 Contract manufacturing 4 132 83 59 56 Other 5 1 115 1 277 -13 -5 Total Established Brands 4, 5 3 014 3 651 -17 -13 Total division net sales to third parties 4, 5 11 243 10 525 7 9 1 Lucentis Gilenya 2 3 Xolair 4 5 Coartem nm = not meaningful Innovative Medicines Division net sales to third parties by core therapeutic area; other promoted brands; and established brands First half H1 2023 H1 2022 % change % change USD m USD m 1 USD cc 2 Cardiovascular Entresto 2 915 2 218 31 35 Leqvio 142 36 294 293 Total Cardiovascular 3 057 2 254 36 39 Immunology Cosentyx 2 348 2 434 -4 -1 Xolair 3 716 720 -1 3 Ilaris 644 560 15 18 Other 1 nm nm Total Immunology 3 708 3 715 0 2 Neuroscience Kesimpta 873 434 101 103 Zolgensma 620 742 -16 -15 Mayzent 183 164 12 13 Aimovig 128 109 17 21 Other 1 nm nm Total Neuroscience 1 804 1 450 24 26 Solid Tumors Tafinlar Mekinist 954 855 12 15 Kisqali 908 547 66 73 Pluvicto 451 12 nm nm Lutathera 299 211 42 43 Piqray/Vijoice 246 158 56 57 Votrient 211 253 -17 -15 Tabrecta 77 61 26 27 Other 1 nm nm Total Solid Tumors 3 147 2 097 50 54 Hematology Promacta/Revolade 1 130 1 025 10 13 Tasigna 938 959 -2 1 Jakavi 849 787 8 12 Kymriah 264 263 0 3 Scemblix 182 56 225 228 Adakveo 105 93 13 13 Other 1 nm nm Total Hematology 3 468 3 184 9 12 Other Promoted Brands Ultibro 228 258 -12 -8 Xiidra 185 233 -21 -21 Beovu 104 102 2 5 Other respiratory 48 39 23 31 Total Other Promoted Brands 565 632 -11 -8 Total Promoted Brands 15 749 13 332 18 21 Established Brands Lucentis 811 1 021 -21 -17 Sandostatin 660 638 3 5 Gilenya 501 1 160 -57 -56 Exforge 370 399 -7 -3 Galvus 358 438 -18 -12 Diovan 313 350 -11 -5 Gleevec/Glivec 289 392 -26 -23 Afinitor/Votubia 226 281 -20 -17 Contract manufacturing 4 255 182 40 41 Other 5 2 281 2 562 -11 -4 Total Established Brands 4, 5 6 064 7 423 -18 -14 Total division net sales to third parties 4, 5 21 813 20 755 5 8 1 Lucentis Gilenya 2 3 Xolair 4 5 Coartem nm = not meaningful Net sales to third parties of the top 20 Innovative Medicines Division brands in 2023 Second quarter US Rest of world Total Brands Brand classification by therapeutic area, other promoted brands or established brands Key indications USD m % change USD/cc 1 USD m % change USD % change cc 1 USD m % change USD % change cc 1 Entresto Cardiovascular Chronic heart failure, hypertension 755 38 761 32 36 1 516 35 37 Cosentyx Immunology Psoriasis (PsO), ankylosing spondylitis (AS), psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSPA) 650 -12 622 15 18 1 272 0 1 Promacta/Revolade Hematology Immune thrombocytopenia (ITP), severe aplastic anemia (SAA) 313 16 270 2 5 583 9 11 Tafinlar Mekinist Solid Tumors BRAF V600+ metastatic adjuvant melanoma, advanced non-small cell lung cancer (NSCLC), tumor agnostic with BRAF mutation indication 196 13 300 8 12 496 10 13 Tasigna Hematology Chronic myeloid leukemia (CML) 232 6 244 -13 -10 476 -4 -3 Kisqali Solid Tumors HR+/HER2- metastatic breast cancer 224 104 269 36 45 493 60 66 Kesimpta Neuroscience Relapsing-remitting multiple sclerosis (RRMS) 373 83 116 231 226 489 105 105 Jakavi Hematology Myelofibrosis (MF), polycytomia vera (PV), graft-versus-host disease (GvHD) 435 9 11 435 9 11 Lucentis Established Brands 2 Age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO) 395 -21 -20 395 -21 -20 Xolair 3 Immunology Severe allergic asthma (SAA), chronic spontaneous urticaria (CSU), nasal polyps 362 3 5 362 3 5 Sandostatin Established Brands Carcinoid tumors, acromegaly 203 -2 128 15 18 331 4 5 Ilaris Immunology Auto-inflammatory (CAPS, TRAPS, HIDS/MKD, FMF, SJIA, AOSD, gout) 163 20 153 10 13 316 15 17 Zolgensma Neuroscience Spinal muscular atrophy (SMA) 84 -32 227 -11 -9 311 -18 -16 Gilenya Established Brands 2 Relapsing multiple sclerosis (RMS) 104 -69 165 -26 -26 269 -52 -52 Pluvicto Solid Tumors PSMA-positive mCRPC patients post-ARPI, post-Taxane 227 nm 13 nm nm 240 nm nm Exforge Established Brands Hypertension 4 33 180 -8 -4 184 -8 -4 Galvus Established Brands Type 2 diabetes 175 -21 -15 175 -21 -15 Diovan Established Brands Hypertension 12 -14 143 -1 4 155 -3 2 Lutathera Solid Tumors GEP-NETs gastroenteropancreatic neuroendocrine tumors 106 108 44 26 28 150 74 75 Gleevec/Glivec Established Brands Chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GIST) 39 -32 103 -25 -21 142 -27 -24 Top 20 brands total 3 685 15 5 105 4 8 8 790 9 11 Rest of portfolio 4 818 5 1 635 -2 5 2 453 0 5 Total division net sales to third parties 4 4 503 14 6 740 3 7 11 243 7 9 1 2 Lucentis Gilenya 3 Xolair 4 Coartem nm = not meaningful Net sales to third parties of the top 20 Innovative Medicines Division brands in 2023 First half US Rest of world Total Brands Brand classification by therapeutic area, other promoted brands or established brands Key indications USD m % change USD/cc 1 USD m % change USD % change cc 1 USD m % change USD % change cc 1 Entresto Cardiovascular Chronic heart failure, hypertension 1 459 34 1 456 29 35 2 915 31 35 Cosentyx Immunology Psoriasis (PsO), ankylosing spondylitis (AS), psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSPA) 1 178 -16 1 170 13 18 2 348 -4 -1 Promacta/Revolade Hematology Immune thrombocytopenia (ITP), severe aplastic anemia (SAA) 590 14 540 6 11 1 130 10 13 Tafinlar Mekinist Solid Tumors BRAF V600+ metastatic adjuvant melanoma, advanced non-small cell lung cancer (NSCLC), tumor agnostic with BRAF mutation indication 390 19 564 7 13 954 12 15 Tasigna Hematology Chronic myeloid leukemia (CML) 443 5 495 -8 -3 938 -2 1 Kisqali Solid Tumors HR+/HER2- metastatic breast cancer 406 115 502 40 50 908 66 73 Kesimpta Neuroscience Relapsing-remitting multiple sclerosis (RRMS) 668 78 205 253 261 873 101 103 Jakavi Hematology Myelofibrosis (MF), polycytomia vera (PV), graft-versus-host disease (GvHD) 849 8 12 849 8 12 Lucentis Established Brands 2 Age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO) 811 -21 -17 811 -21 -17 Xolair 3 Immunology Severe allergic asthma (SAA), chronic spontaneous urticaria (CSU), nasal polyps 716 -1 3 716 -1 3 Sandostatin Established Brands Carcinoid tumors, acromegaly 412 1 248 7 12 660 3 5 Ilaris Immunology Auto-inflammatory (CAPS, TRAPS, HIDS/MKD, FMF, SJIA, AOSD, gout) 304 16 340 14 19 644 15 18 Zolgensma Neuroscience Spinal muscular atrophy (SMA) 193 -18 427 -16 -14 620 -16 -15 Gilenya Established Brands 2 Relapsing multiple sclerosis (RMS) 184 -71 317 -39 -37 501 -57 -56 Pluvicto Solid Tumors PSMA-positive mCRPC patients post-ARPI, post-Taxane 432 nm 19 nm nm 451 nm nm Exforge Established Brands Hypertension 8 14 362 -8 -3 370 -7 -3 Galvus Established Brands Type 2 diabetes 358 -18 -12 358 -18 -12 Diovan Established Brands Hypertension 27 0 286 -11 -5 313 -11 -5 Lutathera Solid Tumors GEP-NETs gastroenteropancreatic neuroendocrine tumors 210 48 89 29 35 299 42 43 Gleevec/Glivec Established Brands Chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GIST) 77 -28 212 -26 -21 289 -26 -23 Top 20 brands total 6 981 14 9 966 2 7 16 947 7 10 Rest of portfolio 4 1 594 7 3 272 -3 4 4 866 0 5 Total division net sales to third parties 4 8 575 12 13 238 1 6 21 813 5 8 1 2 Lucentis Gilenya 3 Xolair 4 Coartem nm = not meaningful Sandoz Division net sales to third parties by business franchise Second quarter Q2 2022 1 USD m USD m USD cc 2 Generics 1 848 1 783 4 6 Biosimilars 531 473 12 13 Total division net sales to third parties 2 379 2 256 5 8 1 Coartem 2 First half H1 2022 1 USD m USD m USD cc 2 Generics 3 713 3 619 3 6 Biosimilars 1 049 938 12 15 Total division net sales to third parties 4 762 4 557 4 8 1 Coartem 2 The product portfolio of Sandoz is widely spread in 2023 and 2022. Segmentation – Other revenue Second quarter Innovative Medicines Sandoz Corporate Group (USD millions) Q2 2023 Q2 2022 Q2 2023 Q2 2022 Q2 2023 Q2 2022 Q2 2023 Q2 2022 Profit sharing income 246 223 246 223 Royalty income 19 3 4 4 2 23 9 Milestone income 25 20 1 25 21 Other 1 14 49 2 2 4 20 51 Total other revenues 304 295 6 7 4 2 314 304 1 First half Innovative Medicines Sandoz Corporate Group (USD millions) H1 2023 H1 2022 H1 2023 H1 2022 H1 2023 H1 2022 H1 2023 H1 2022 Profit sharing income 445 428 445 428 Royalty income 41 6 8 9 5 49 20 Milestone income 28 39 1 28 40 Other 1 36 96 4 3 7 47 99 Total other revenues 550 569 12 13 7 5 569 587 1 |
Subsequent events
Subsequent events | 6 Months Ended |
Jun. 30, 2023 | |
Disclosure of non-adjusting events after reporting period [abstract] | |
Events subsequent to the December 31 consolidated balance sheet date | 10. Events subsequent to the June 30, 2023, consolidated balance sheet Significant transactions closed in July 2023 In the second quarter of 2023, Novartis entered into an agreement to acquire DTx Pharma Inc. (DTx), a San-Diego US based, pre-clinical stage biotechnology company focused on leveraging its proprietary FALCON platform to develop siRNA therapies for neuroscience indications. The transaction was completed on July 14, 2023. For details see Note 3, “Significant pending transactions entered into in second quarter 2023 and closed in July 2023.” |
Selected critical accounting _2
Selected critical accounting policies (Policies) | 6 Months Ended |
Jun. 30, 2023 | |
Significant Accounting Policies [abstract] | |
Description of other accounting policies relevant to understanding of financial statements [text block] | The Group’s principal accounting policies are set out in Note 1 to the Consolidated Financial Statements in the 2022 Annual Report and conform with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board. The preparation of interim financial statements requires management to make certain estimates and assumptions, either at the balance sheet date or during the period, which affect the reported amounts of revenues, expenses, assets, liabilities and contingent amounts. Estimates are based on historical experience and other assumptions that are considered reasonable under the given circumstances and are regularly monitored. Actual outcomes and results could differ from those estimates and assumptions. Revisions to estimates are recognized in the period in which the estimate is revised. As disclosed in the 2022 Annual Report, goodwill, and acquired In-Process Research & Development projects are reviewed for impairment at least annually and these, as well as all other investments in intangible assets, are reviewed for impairment whenever an event or decision occurs that raises concern about their balance sheet carrying value. The amount of goodwill and other intangible assets on the Group’s consolidated balance sheet has risen significantly in recent years, primarily from acquisitions. Impairment testing may lead to potentially significant impairment charges in the future that could have a materially adverse impact on the Group’s results of operations and financial condition. The Group’s activities are not subject to significant seasonal fluctuations. |
Summary of equity attributabl_2
Summary of equity attributable to Novartis AG shareholders (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Disclosure of equity [abstract] | |
Summary of treasury shares movements [table text block] | Number of outstanding shares (in millions) Issued share capital and reserves attributable to Novartis AG shareholders (in USD millions) Note 2023 2022 H1 2023 H1 2022 Balance at beginning of year 2 119.6 2 234.9 59 342 67 655 Shares acquired to be canceled -61.3 -61.7 -5 767 -5 381 Other share purchases -1.3 -1.2 -121 -109 Exercise of options and employee transactions 4.1 2.8 1.9 153 91 Equity-based compensation 8.5 8.9 433 437 Shares delivered to Alcon employees as a result of the Alcon spin-off 0.0 5 Taxes on treasury share transactions 8 11 Decrease of treasury share repurchase obligation Dividends -7 255 -7 506 Net income of the period attributable to shareholders of Novartis AG 4 609 3 916 Other comprehensive income attributable to shareholders of Novartis AG 387 857 Other movements 4.3 58 140 Balance at June 30 2 068.3 2 182.8 51 847 62 925 |
Financial instruments (Tables)
Financial instruments (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Financial Instruments - additional disclosure [abstract] | |
Disclosure of fair value measurement [text block] | Level 1 Level 2 Level 3 Total Jun 30, Dec 31, Jun 30, Dec 31, Jun 30, Dec 31, Jun 30, Dec 31, Financial assets Cash and cash equivalents Debt securities 49 49 Total cash and cash equivalents at fair value 49 49 Marketable securities Debt securities 8 9 8 9 Derivative financial instruments 102 204 102 204 Total marketable securities and derivative financial instruments at fair value 110 213 110 213 Current contingent consideration receivables 58 43 58 43 Long-term financial investments Debt and equity securities 488 473 11 10 599 699 1 098 1 182 Fund investments 7 20 194 261 201 281 Non-current contingent consideration receivables 675 607 675 607 Total long-term financial investments at fair value 495 493 11 10 1 468 1 567 1 974 2 070 Associated companies at fair value through profit or loss 114 129 114 129 Financial liabilities Current contingent consideration liabilities -29 -131 -29 -131 Current other financial liabilities -189 -189 Derivative financial instruments -40 -55 -40 -55 Total current financial liabilities at fair value -40 -55 -218 -131 -258 -186 Non-current contingent consideration liabilities -593 -704 -593 -704 Non-current other financial liabilities -232 -232 Total non-current financial liabilities at fair value -593 -936 -593 -936 |
Details to the consolidated s_2
Details to the consolidated statements of cash flows (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Disclosure of details to the consolidated statements of cash flows [abstract] | |
Adjustments for non-cash items from continuing operations [table text block] | (USD millions) Q2 2023 Q2 2022 Depreciation, amortization and impairments on: Property, plant and equipment 262 507 Right-of-use assets 77 76 Intangible assets 1 486 1 219 Financial assets 1 28 97 Change in provisions and other non-current liabilities 73 547 Losses/(gains) on disposal and other adjustments on property, plant and equipment; intangible assets; -114 Equity-settled compensation expense 233 204 Loss from associated companies 2 Income taxes 452 347 Net financial expense 149 186 Other 36 -8 Total 2 883 3 061 1 (USD millions) H1 2023 H1 2022 Depreciation, amortization and impairments on: Property, plant and equipment 565 821 Right-of-use assets 151 154 Intangible assets 3 105 2 232 Financial assets 1 75 199 Change in provisions and other non-current liabilities 585 635 Gains on disposal and other adjustments on property, plant and equipment; intangible assets; -217 -192 Equity-settled compensation expense 432 407 Loss from associated companies 3 2 Income taxes 898 797 Net financial expense 264 367 Other 29 -8 Total 5 890 5 414 1 In the second quarter of 2023, there were no additions to intangible assets (Q2 2022: nil; other than through business combinations) with deferred payments. In the second quarter of 2023, there were USD 74 million (Q2 2022: USD 79 million) additions to right-of-use assets recognized. In the first half of 2023, there were no additions to intangible assets with deferred payments. In the first half of 2022, other than through business combinations, there were USD 0.3 billion additions to intangible assets with deferred payments. In the first half of 2023, there were USD 225 million (H1 2022: USD 122 million) additions to right-of-use assets recognized. |
Cash flows from changes in working capital and other operating items included in operating cash flow [table text block] | (USD millions) Q2 2023 Q2 2022 H1 2023 H1 2022 Increase in inventories -376 -194 -996 -619 Increase in trade receivables -425 -413 -1 275 -909 Increase/(decrease) in trade payables 127 11 214 -132 Change in other current and non-current assets -111 70 -288 -293 Change in other current liabilities 623 472 679 -112 Total -162 -54 -1 666 -2 065 |
Cash flows arising from acquisitions and divestments of businesses [table text block] | (USD millions) Q2 2023 Q2 2022 H1 2023 H1 2022 Net assets recognized as a result of acquisitions of businesses 0 -107 0 -1 086 Fair value of previously held equity interests 24 24 Contingent consideration payable, net 31 -26 212 Payments (incl. prepayments), deferred consideration and other adjustments, net -100 12 -100 -13 Cash flows used for acquisitions of businesses -100 -40 -126 -863 Cash flows from/(used for) divestments of businesses, net 1 16 -19 3 -17 Cash flows used for acquisitions and divestments of businesses, net -84 -59 -123 -880 1 In the first half of 2023, USD 3 million (Q2 2023: USD 16 million) represented the net cash inflows from divestments in prior years. In the first half of 2022, USD 17 million (Q2 2022: USD 19 million) net cash outflows from divestments of businesses included USD 20 million (Q2 2022: USD 20 million) reduction to cash and cash equivalents due to the derecognized cash and cash equivalents following a loss of control of a company upon expiry of an option to purchase the company, partly offset by net cash inflows of USD 3 million (Q2 2022: USD 1 million) from business divestments in the 2022 periods and in prior years. In the first half of 2022, the net identifiable assets of divested businesses amounted to USD 140 million (Q2 2022: USD 106 million), comprised of non-current assets of USD 118 million (Q2 2022: USD 113 million), current assets of USD 65 million (Q2 2022: USD 36 million), including USD 29 million (Q2 2022: USD 20 million) cash and cash equivalents and of non-current and current liabilities of USD 43 million (Q2 2022: USD 43 million). The deferred sale price receivable and other adjustments amounted to USD 25 million (Q2 2022: nil). |
Acquisition of businesses (Tabl
Acquisition of businesses (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Disclosure of acquisition of businesses [abstract] | |
Fair value of assets and liabilities arising from acquisitions [table text block] | (USD millions) H1 2023 H1 2022 Property, plant and equipment 13 Right-of-use assets 12 Acquired research and development 1 223 Deferred tax assets 53 Other current assets 5 Cash and cash equivalents 89 Deferred tax liabilities -303 Current and non-current lease liabilities -12 Trade payables and other liabilities -68 Net identifiable assets acquired 0 1 012 Acquired cash and cash equivalents -89 Goodwill 163 Net assets recognized as a result of acquisitions of businesses 0 1 086 |
Segmentation of key figures (Ta
Segmentation of key figures (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Statement [line items] | |
Segmentation - Consolidated income statements | Second quarter Innovative Medicines Sandoz Corporate (including eliminations) 1 Group Q2 2022 2 Q2 2022 2 Q2 2022 2 Net sales to third parties 11 243 10 525 2 379 2 256 13 622 12 781 Sales to other segments 192 178 57 55 -249 -233 Net sales 11 435 10 703 2 436 2 311 -249 -233 13 622 12 781 Other revenues 304 295 6 7 4 2 314 304 Cost of goods sold -3 338 -2 773 -1 250 -1 212 247 234 -4 341 -3 751 Gross profit 8 401 8 225 1 192 1 106 2 3 9 595 9 334 Selling, general and administration -2 955 -2 956 -594 -503 -137 -122 -3 686 -3 581 Research and development -2 304 -2 302 -222 -196 -2 526 -2 498 Other income 108 207 14 23 25 73 147 303 Other expense -251 -968 -178 -73 -181 -289 -610 -1 330 Operating income 2 999 2 206 212 357 -291 -335 2 920 2 228 as % of net sales 26.7% 21.0% 8.9% 15.8% 21.4% 17.4% Loss from associated companies 1 1 -2 -2 -2 Interest expense -224 -202 Other financial income and expense 75 16 Income before taxes 2 769 2 042 Income taxes -452 -347 Net income 2 317 1 695 1 2 Coartem First half Innovative Medicines Sandoz Corporate (including eliminations) 1 Group H1 2022 2 H1 2022 2 H1 2022 2 Net sales to third parties 21 813 20 755 4 762 4 557 26 575 25 312 Sales to other segments 424 388 149 102 -573 -490 Net sales 22 237 21 143 4 911 4 659 -573 -490 26 575 25 312 Other revenues 550 569 12 13 7 5 569 587 Cost of goods sold -6 328 -5 695 -2 517 -2 434 573 522 -8 272 -7 607 Gross profit 16 459 16 017 2 406 2 238 7 37 18 872 18 292 Selling, general and administration -5 715 -5 842 -1 136 -1 016 -278 -235 -7 129 -7 093 Research and development -4 879 -4 414 -441 -404 -5 320 -4 818 Other income 859 352 24 71 234 106 1 117 529 Other expense -1 050 -1 280 -322 -138 -392 -412 -1 764 -1 830 Operating income 5 674 4 833 531 751 -429 -504 5 776 5 080 as % of net sales 26.0% 23.3% 11.2% 16.5% 21.7% 20.1% Loss from associated companies 1 1 1 1 -5 -4 -3 -2 Interest expense -435 -403 Other financial income and expense 171 36 Income before taxes 5 509 4 711 Income taxes -898 -797 Net income 4 611 3 914 1 2 Coartem |
Segmentation - Consolidated balance sheets | Innovative Medicines Sandoz Corporate (including eliminations) 1 Group Dec 31, Dec 31, Total assets 2 75 633 75 836 16 677 15 752 18 669 25 865 110 979 117 453 Total liabilities -16 942 -16 966 -4 195 -3 710 -37 911 -37 354 -59 048 -58 030 Total equity 51 931 59 423 Net debt 3 15 374 7 245 15 374 7 245 Net operating assets 2 58 691 58 870 12 482 12 042 -3 868 -4 244 67 305 66 668 Included in net operating assets are: Property, plant and equipment 8 463 8 488 1 965 1 861 397 415 10 825 10 764 Goodwill 2 21 992 21 857 7 530 7 444 29 522 29 301 Intangible assets other than goodwill 26 152 29 826 1 427 1 460 424 358 28 003 31 644 1 2 Coartem 3 |
Disclosure of impairment loss, reversal of impairment loss and additions to restructuring provisions | Second quarter Innovative Medicines Sandoz Corporate Group (USD millions) Q2 2023 Q2 2022 Q2 2023 Q2 2022 Q2 2023 Q2 2022 Q2 2023 Q2 2022 Property, plant and equipment impairment charges -31 -236 -1 -1 -32 -237 Property, plant and equipment impairment reversals 39 1 2 40 2 Intangible assets impairment charges 1 -453 -226 -2 -4 -455 -230 Additions to restructuring provisions -33 -316 -11 -20 -23 -162 -67 -498 1 The second quarter of 2023 includes an impairment of USD 0.3 billion for the write-down of a currently marketed product to reflect reduction in recoverable amount. First half Innovative Medicines Sandoz Corporate Group (USD millions) H1 2023 H1 2022 H1 2023 H1 2022 H1 2023 H1 2022 H1 2023 H1 2022 Property, plant and equipment impairment charges -58 -258 -2 -1 -1 -60 -260 Property, plant and equipment impairment reversal 48 2 1 3 49 5 Right-of-use assets impaiment charges -1 -1 Intangible assets impairment charges 1 -926 -263 -14 -4 -940 -267 Additions to restructuring provisions -411 -360 -16 -30 -55 -172 -482 -562 1 The first half of 2023 includes an impairment of USD 0.3 billion due to the write-down of IPR&D related to cessation of clinical development program NIZ985 and of USD 0.3 billion for the write-down of a currently marketed product to reflect reduction in recoverable amount. In the first half of 2023, there were no nil nil |
Restructuring provisions movements | Restructuring provisions movements (USD millions) Q2 2023 Q2 2022 H1 2023 H1 2022 Balance at beginning of period 1 209 331 1 131 345 Additions 67 498 482 562 Cash payments -173 -76 -490 -144 Releases -63 -10 -95 -15 Transfers 1 -1 0 Currency translation effects 4 -11 17 -17 Balance at closing of period 1 045 731 1 045 731 In the first half of 2023, additions to provisions of USD 482 million (Q2: USD 67 million) were mainly related to the continuation of the initiative announced in April 2022, to implement a new streamlined organizational model designed to support innovation, growth and productivity. In the first half of 2022, additions to provisions of USD 562 million (Q2: USD 498 million) were mainly related to the initiative announced in April 2022, to implement a new streamlined organizational model designed to support innovation, growth and productivity, as well as, to the continuation of the Innovative Medicines Division and the Operations unit 2021 restructuring initiatives. |
Net sales by region | Second quarter Q2 2022 2 3 Innovative Medicines Europe 3 496 3 481 0 2 31 33 US 4 503 3 967 14 14 40 38 Asia/Africa/Australasia 2 418 2 328 4 10 22 22 Canada and Latin America 826 749 10 19 7 7 Total 11 243 10 525 7 9 100 100 Of which in Established Markets 8 276 7 742 7 7 74 74 Of which in Emerging Growth Markets 2 967 2 783 7 17 26 26 Sandoz Europe 1 329 1 192 11 13 56 53 US 378 411 -8 -8 16 18 Asia/Africa/Australasia 395 406 -3 4 17 18 Canada and Latin America 277 247 12 16 11 11 Total 2 379 2 256 5 8 100 100 Of which in Established Markets 1 685 1 581 7 7 71 70 Of which in Emerging Growth Markets 694 675 3 10 29 30 Group Europe 4 825 4 673 3 5 35 37 US 4 881 4 378 11 11 36 34 Asia/Africa/Australasia 2 813 2 734 3 9 21 21 Canada and Latin America 1 103 996 11 18 8 8 Total 13 622 12 781 7 9 100 100 Of which in Established Markets 9 961 9 323 7 7 73 73 Of which in Emerging Growth Markets 3 661 3 458 6 15 27 27 1 2 Coartem 3 Net sales by region 1 First half H1 2022 2 3 Innovative Medicines Europe 6 917 7 010 -1 2 32 34 US 8 575 7 642 12 12 39 37 Asia/Africa/Australasia 4 717 4 656 1 9 22 22 Canada and Latin America 1 604 1 447 11 19 7 7 Total 21 813 20 755 5 8 100 100 Of which in Established Markets 15 954 15 314 4 6 73 74 Of which in Emerging Growth Markets 5 859 5 441 8 16 27 26 Sandoz Europe 2 695 2 427 11 14 57 53 US 758 819 -7 -7 16 18 Asia/Africa/Australasia 772 811 -5 4 16 18 Canada and Latin America 537 500 7 11 11 11 Total 4 762 4 557 4 8 100 100 Of which in Established Markets 3 330 3 155 6 8 70 69 Of which in Emerging Growth Markets 1 432 1 402 2 8 30 31 Group Europe 9 612 9 437 2 5 36 37 US 9 333 8 461 10 10 35 33 Asia/Africa/Australasia 5 489 5 467 0 8 21 22 Canada and Latin America 2 141 1 947 10 17 8 8 Total 26 575 25 312 5 8 100 100 Of which in Established Markets 19 284 18 469 4 6 73 73 Of which in Emerging Growth Markets 7 291 6 843 7 15 27 27 1 2 Coartem 3 |
Other revenue | Second quarter Innovative Medicines Sandoz Corporate Group (USD millions) Q2 2023 Q2 2022 Q2 2023 Q2 2022 Q2 2023 Q2 2022 Q2 2023 Q2 2022 Profit sharing income 246 223 246 223 Royalty income 19 3 4 4 2 23 9 Milestone income 25 20 1 25 21 Other 1 14 49 2 2 4 20 51 Total other revenues 304 295 6 7 4 2 314 304 1 First half Innovative Medicines Sandoz Corporate Group (USD millions) H1 2023 H1 2022 H1 2023 H1 2022 H1 2023 H1 2022 H1 2023 H1 2022 Profit sharing income 445 428 445 428 Royalty income 41 6 8 9 5 49 20 Milestone income 28 39 1 28 40 Other 1 36 96 4 3 7 47 99 Total other revenues 550 569 12 13 7 5 569 587 1 |
Innovative Medicines | |
Statement [line items] | |
Net sales | Innovative Medicines Division net sales to third parties by core therapeutic area; other promoted brands; and established brands Second quarter Q2 2023 Q2 2022 % change % change USD m USD m 1 USD cc 2 Cardiovascular Entresto 1 516 1 125 35 37 Leqvio 78 22 255 249 Total Cardiovascular 1 594 1 147 39 41 Immunology Cosentyx 1 272 1 275 0 1 Xolair 3 362 352 3 5 Ilaris 316 275 15 17 Total Immunology 1 950 1 902 3 4 Neuroscience Kesimpta 489 239 105 105 Zolgensma 311 379 -18 -16 Mayzent 94 85 11 11 Aimovig 67 55 22 24 Total Neuroscience 961 758 27 28 Solid Tumors Tafinlar Mekinist 496 452 10 13 Kisqali 493 308 60 66 Pluvicto 240 10 nm nm Lutathera 150 86 74 75 Piqray/Vijoice 130 85 53 54 Votrient 106 124 -15 -13 Tabrecta 41 30 37 37 Total Solid Tumors 1 656 1 095 51 54 Hematology Promacta/Revolade 583 534 9 11 Tasigna 476 498 -4 -3 Jakavi 435 398 9 11 Kymriah 129 136 -5 -5 Scemblix 106 31 242 248 Adakveo 53 49 8 8 Total Hematology 1 782 1 646 8 10 Other Promoted Brands Ultibro 114 126 -10 -8 Xiidra 96 126 -24 -24 Beovu 53 54 -2 0 Other respiratory 23 20 15 22 Total Other Promoted Brands 286 326 -12 -11 Total Promoted Brands 8 229 6 874 20 22 Established Brands Lucentis 395 501 -21 -20 Sandostatin 331 318 4 5 Gilenya 269 555 -52 -52 Exforge 184 199 -8 -4 Galvus 175 222 -21 -15 Diovan 155 159 -3 2 Gleevec/Glivec 142 194 -27 -24 Afinitor/Votubia 116 143 -19 -17 Contract manufacturing 4 132 83 59 56 Other 5 1 115 1 277 -13 -5 Total Established Brands 4, 5 3 014 3 651 -17 -13 Total division net sales to third parties 4, 5 11 243 10 525 7 9 1 Lucentis Gilenya 2 3 Xolair 4 5 Coartem nm = not meaningful Innovative Medicines Division net sales to third parties by core therapeutic area; other promoted brands; and established brands First half H1 2023 H1 2022 % change % change USD m USD m 1 USD cc 2 Cardiovascular Entresto 2 915 2 218 31 35 Leqvio 142 36 294 293 Total Cardiovascular 3 057 2 254 36 39 Immunology Cosentyx 2 348 2 434 -4 -1 Xolair 3 716 720 -1 3 Ilaris 644 560 15 18 Other 1 nm nm Total Immunology 3 708 3 715 0 2 Neuroscience Kesimpta 873 434 101 103 Zolgensma 620 742 -16 -15 Mayzent 183 164 12 13 Aimovig 128 109 17 21 Other 1 nm nm Total Neuroscience 1 804 1 450 24 26 Solid Tumors Tafinlar Mekinist 954 855 12 15 Kisqali 908 547 66 73 Pluvicto 451 12 nm nm Lutathera 299 211 42 43 Piqray/Vijoice 246 158 56 57 Votrient 211 253 -17 -15 Tabrecta 77 61 26 27 Other 1 nm nm Total Solid Tumors 3 147 2 097 50 54 Hematology Promacta/Revolade 1 130 1 025 10 13 Tasigna 938 959 -2 1 Jakavi 849 787 8 12 Kymriah 264 263 0 3 Scemblix 182 56 225 228 Adakveo 105 93 13 13 Other 1 nm nm Total Hematology 3 468 3 184 9 12 Other Promoted Brands Ultibro 228 258 -12 -8 Xiidra 185 233 -21 -21 Beovu 104 102 2 5 Other respiratory 48 39 23 31 Total Other Promoted Brands 565 632 -11 -8 Total Promoted Brands 15 749 13 332 18 21 Established Brands Lucentis 811 1 021 -21 -17 Sandostatin 660 638 3 5 Gilenya 501 1 160 -57 -56 Exforge 370 399 -7 -3 Galvus 358 438 -18 -12 Diovan 313 350 -11 -5 Gleevec/Glivec 289 392 -26 -23 Afinitor/Votubia 226 281 -20 -17 Contract manufacturing 4 255 182 40 41 Other 5 2 281 2 562 -11 -4 Total Established Brands 4, 5 6 064 7 423 -18 -14 Total division net sales to third parties 4, 5 21 813 20 755 5 8 1 Lucentis Gilenya 2 3 Xolair 4 5 Coartem nm = not meaningful |
Net sales of Top 20 products | Net sales to third parties of the top 20 Innovative Medicines Division brands in 2023 Second quarter US Rest of world Total Brands Brand classification by therapeutic area, other promoted brands or established brands Key indications USD m % change USD/cc 1 USD m % change USD % change cc 1 USD m % change USD % change cc 1 Entresto Cardiovascular Chronic heart failure, hypertension 755 38 761 32 36 1 516 35 37 Cosentyx Immunology Psoriasis (PsO), ankylosing spondylitis (AS), psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSPA) 650 -12 622 15 18 1 272 0 1 Promacta/Revolade Hematology Immune thrombocytopenia (ITP), severe aplastic anemia (SAA) 313 16 270 2 5 583 9 11 Tafinlar Mekinist Solid Tumors BRAF V600+ metastatic adjuvant melanoma, advanced non-small cell lung cancer (NSCLC), tumor agnostic with BRAF mutation indication 196 13 300 8 12 496 10 13 Tasigna Hematology Chronic myeloid leukemia (CML) 232 6 244 -13 -10 476 -4 -3 Kisqali Solid Tumors HR+/HER2- metastatic breast cancer 224 104 269 36 45 493 60 66 Kesimpta Neuroscience Relapsing-remitting multiple sclerosis (RRMS) 373 83 116 231 226 489 105 105 Jakavi Hematology Myelofibrosis (MF), polycytomia vera (PV), graft-versus-host disease (GvHD) 435 9 11 435 9 11 Lucentis Established Brands 2 Age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO) 395 -21 -20 395 -21 -20 Xolair 3 Immunology Severe allergic asthma (SAA), chronic spontaneous urticaria (CSU), nasal polyps 362 3 5 362 3 5 Sandostatin Established Brands Carcinoid tumors, acromegaly 203 -2 128 15 18 331 4 5 Ilaris Immunology Auto-inflammatory (CAPS, TRAPS, HIDS/MKD, FMF, SJIA, AOSD, gout) 163 20 153 10 13 316 15 17 Zolgensma Neuroscience Spinal muscular atrophy (SMA) 84 -32 227 -11 -9 311 -18 -16 Gilenya Established Brands 2 Relapsing multiple sclerosis (RMS) 104 -69 165 -26 -26 269 -52 -52 Pluvicto Solid Tumors PSMA-positive mCRPC patients post-ARPI, post-Taxane 227 nm 13 nm nm 240 nm nm Exforge Established Brands Hypertension 4 33 180 -8 -4 184 -8 -4 Galvus Established Brands Type 2 diabetes 175 -21 -15 175 -21 -15 Diovan Established Brands Hypertension 12 -14 143 -1 4 155 -3 2 Lutathera Solid Tumors GEP-NETs gastroenteropancreatic neuroendocrine tumors 106 108 44 26 28 150 74 75 Gleevec/Glivec Established Brands Chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GIST) 39 -32 103 -25 -21 142 -27 -24 Top 20 brands total 3 685 15 5 105 4 8 8 790 9 11 Rest of portfolio 4 818 5 1 635 -2 5 2 453 0 5 Total division net sales to third parties 4 4 503 14 6 740 3 7 11 243 7 9 1 2 Lucentis Gilenya 3 Xolair 4 Coartem nm = not meaningful Net sales to third parties of the top 20 Innovative Medicines Division brands in 2023 First half US Rest of world Total Brands Brand classification by therapeutic area, other promoted brands or established brands Key indications USD m % change USD/cc 1 USD m % change USD % change cc 1 USD m % change USD % change cc 1 Entresto Cardiovascular Chronic heart failure, hypertension 1 459 34 1 456 29 35 2 915 31 35 Cosentyx Immunology Psoriasis (PsO), ankylosing spondylitis (AS), psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSPA) 1 178 -16 1 170 13 18 2 348 -4 -1 Promacta/Revolade Hematology Immune thrombocytopenia (ITP), severe aplastic anemia (SAA) 590 14 540 6 11 1 130 10 13 Tafinlar Mekinist Solid Tumors BRAF V600+ metastatic adjuvant melanoma, advanced non-small cell lung cancer (NSCLC), tumor agnostic with BRAF mutation indication 390 19 564 7 13 954 12 15 Tasigna Hematology Chronic myeloid leukemia (CML) 443 5 495 -8 -3 938 -2 1 Kisqali Solid Tumors HR+/HER2- metastatic breast cancer 406 115 502 40 50 908 66 73 Kesimpta Neuroscience Relapsing-remitting multiple sclerosis (RRMS) 668 78 205 253 261 873 101 103 Jakavi Hematology Myelofibrosis (MF), polycytomia vera (PV), graft-versus-host disease (GvHD) 849 8 12 849 8 12 Lucentis Established Brands 2 Age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO) 811 -21 -17 811 -21 -17 Xolair 3 Immunology Severe allergic asthma (SAA), chronic spontaneous urticaria (CSU), nasal polyps 716 -1 3 716 -1 3 Sandostatin Established Brands Carcinoid tumors, acromegaly 412 1 248 7 12 660 3 5 Ilaris Immunology Auto-inflammatory (CAPS, TRAPS, HIDS/MKD, FMF, SJIA, AOSD, gout) 304 16 340 14 19 644 15 18 Zolgensma Neuroscience Spinal muscular atrophy (SMA) 193 -18 427 -16 -14 620 -16 -15 Gilenya Established Brands 2 Relapsing multiple sclerosis (RMS) 184 -71 317 -39 -37 501 -57 -56 Pluvicto Solid Tumors PSMA-positive mCRPC patients post-ARPI, post-Taxane 432 nm 19 nm nm 451 nm nm Exforge Established Brands Hypertension 8 14 362 -8 -3 370 -7 -3 Galvus Established Brands Type 2 diabetes 358 -18 -12 358 -18 -12 Diovan Established Brands Hypertension 27 0 286 -11 -5 313 -11 -5 Lutathera Solid Tumors GEP-NETs gastroenteropancreatic neuroendocrine tumors 210 48 89 29 35 299 42 43 Gleevec/Glivec Established Brands Chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GIST) 77 -28 212 -26 -21 289 -26 -23 Top 20 brands total 6 981 14 9 966 2 7 16 947 7 10 Rest of portfolio 4 1 594 7 3 272 -3 4 4 866 0 5 Total division net sales to third parties 4 8 575 12 13 238 1 6 21 813 5 8 1 2 Lucentis Gilenya 3 Xolair 4 Coartem nm = not meaningful |
Sandoz [member] | |
Statement [line items] | |
Net sales | Second quarter Q2 2022 1 USD m USD m USD cc 2 Generics 1 848 1 783 4 6 Biosimilars 531 473 12 13 Total division net sales to third parties 2 379 2 256 5 8 1 Coartem 2 First half H1 2022 1 USD m USD m USD cc 2 Generics 3 713 3 619 3 6 Biosimilars 1 049 938 12 15 Total division net sales to third parties 4 762 4 557 4 8 1 Coartem 2 The product portfolio of Sandoz is widely spread in 2023 and 2022. |
Significant transactions (Detai
Significant transactions (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | |||||
Jun. 12, 2023 | Feb. 17, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | Dec. 31, 2022 | |
Disclosure of detailed information about business combination [line items] | |||||||
Identifiable assets acquired (liabilities assumed) | $ 0 | $ 1,086 | $ 0 | $ 1,086 | |||
Intangible assets other than goodwill | 28,003 | 28,003 | $ 31,644 | ||||
Revenue from sale of goods | 13,622 | 12,781 | 26,575 | 25,312 | |||
Innovative Medicines | |||||||
Disclosure of detailed information about business combination [line items] | |||||||
Intangible assets other than goodwill | 26,152 | 26,152 | 29,826 | ||||
Revenue from sale of goods | 11,435 | 10,703 | 22,237 | 21,143 | |||
Sandoz | |||||||
Disclosure of detailed information about business combination [line items] | |||||||
Intangible assets other than goodwill | 1,427 | 1,427 | 1,460 | ||||
Revenue from sale of goods | 2,436 | 2,311 | 4,911 | 4,659 | |||
Corporate | |||||||
Disclosure of detailed information about business combination [line items] | |||||||
Intangible assets other than goodwill | 424 | 424 | $ 358 | ||||
Revenue from sale of goods | (249) | $ (233) | $ (573) | $ (490) | |||
Gyroscope Therapeutics Holdings plc. | Innovative Medicines | |||||||
Disclosure of detailed information about business combination [line items] | |||||||
Consideration transferred, acquisition-date fair value | $ 1,000 | ||||||
Portion of consideration paid consisting of cash and cash equivalents upfront payment | (800) | ||||||
Identifiable assets acquired (liabilities assumed) | 900 | ||||||
Additional recognition, goodwill | 100 | ||||||
Deferred tax liability (asset) | 200 | ||||||
Intangible assets other than goodwill | 1,100 | ||||||
Contingent consideration recognised as of acquisition date | $ 200 | ||||||
Chinook Therapeutics | Innovative Medicines | |||||||
Disclosure of detailed information about business combination [line items] | |||||||
Portion of consideration paid consisting of cash and cash equivalents upfront payment | $ (3,200) | ||||||
Potential milestone maximum payments | $ 300 | ||||||
DTx Pharma, Inc. | Innovative Medicines | |||||||
Disclosure of detailed information about business combination [line items] | |||||||
Portion of consideration paid consisting of cash and cash equivalents upfront payment | (500) | ||||||
Potential milestone maximum payments | $ 500 |
Summary of equity attributabl_3
Summary of equity attributable to Novartis AG shareholders (Details) - USD ($) shares in Millions, $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Disclosure of classes of share capital [line items] | ||||
Equity at beginning of period | $ 52,142 | $ 61,704 | $ 59,423 | $ 67,822 |
Exercise of options and employee transactions, equity impact | (2) | 153 | 91 | |
Equity-based compensation, equity impact | 242 | 204 | 433 | 437 |
Shares delivered to divested business employees, equity impact | 5 | |||
Taxes on treasury shares | 1 | 8 | 11 | |
(Increase)/decrease of treasury share repurchase obligation under a share buyback trading plan | 2,639 | 2,809 | ||
Dividends | (7,255) | (7,506) | ||
Net income | 2,317 | 1,695 | 4,611 | 3,914 |
Other comprehensive income | 219 | (589) | 388 | 853 |
Other movements | 22 | 117 | 58 | 140 |
Equity at end of period | 51,931 | 63,006 | $ 51,931 | $ 63,006 |
Equity attributable to owners of parent [member] | ||||
Disclosure of classes of share capital [line items] | ||||
Number of shares outstanding at beginning of period | 2,119.6 | 2,234.9 | ||
Equity at beginning of period | 52,059 | 61,540 | $ 59,342 | $ 67,655 |
Shares acquired to be cancelled | (61.3) | (61.7) | ||
Shares acquired for cancellation, equity impact | $ (5,767) | $ (5,381) | ||
Other share purchases | (1.3) | (1.2) | ||
Other share purchases, equity impact | $ (121) | $ (109) | ||
Exercise of options and employee transactions shares | 2.8 | 1.9 | ||
Exercise of options and employee transactions, equity impact | (2) | $ 153 | $ 91 | |
Equity based compensation shares | 8.5 | 8.9 | ||
Equity-based compensation, equity impact | 242 | 204 | $ 433 | $ 437 |
Shares delivered to divested business employees | 0 | |||
Shares delivered to divested business employees, equity impact | $ 5 | |||
Taxes on treasury shares | 1 | 8 | 11 | |
(Increase)/decrease of treasury share repurchase obligation under a share buyback trading plan | 2,639 | 2,809 | ||
Dividends | (7,255) | (7,506) | ||
Net income | 2,316 | 1,694 | 4,609 | 3,916 |
Other comprehensive income | 219 | (585) | 387 | 857 |
Other movements | $ 22 | $ 117 | $ 58 | $ 140 |
Number of shares outstanding at end of period | 2,068.3 | 2,182.8 | 2,068.3 | 2,182.8 |
Equity at end of period | $ 51,847 | $ 62,925 | $ 51,847 | $ 62,925 |
Summary of equity attributabl_4
Summary of equity attributable to Novartis AG shareholders (Details 2) $ / shares in Units, Pure in Millions, $ in Billions | 1 Months Ended | 6 Months Ended | ||
Dec. 31, 2021 USD ($) year $ / shares | Jun. 30, 2023 | Mar. 31, 2023 | Dec. 31, 2022 year $ / shares | |
Statement of changes in equity [abstract] | ||||
Maximal amount of share buyback programm | $ | $ 15 | |||
Written call options held by market maker | 3 | 0 | 3 | |
Written call options, contractual live | 10 | |||
Written call options, contractual live, remaining | 2 | 1 | ||
Written call options, weighted average exercise price | $ / shares | $ 61.45 | $ 66.07 | ||
Number of options to be repurchased | 11.7 | |||
Number of written call options exercised | 3 |
Financial instruments (Details)
Financial instruments (Details) - USD ($) $ in Millions | Jun. 30, 2023 | Dec. 31, 2022 |
Cash and cash equivalents [member] | ||
Disclosure of fair value measurement of assets [line items] | ||
Financial assets, at fair value | $ 49 | |
Cash and cash equivalents [member] | Debt securities | ||
Disclosure of fair value measurement of assets [line items] | ||
Financial assets, at fair value | 49 | |
Level 1 of fair value hierarchy [member] | Cash and cash equivalents [member] | ||
Disclosure of fair value measurement of assets [line items] | ||
Financial assets, at fair value | 49 | |
Level 1 of fair value hierarchy [member] | Cash and cash equivalents [member] | Debt securities | ||
Disclosure of fair value measurement of assets [line items] | ||
Financial assets, at fair value | 49 | |
Recurring fair value measurement [member] | ||
Disclosure of fair value measurement of assets [line items] | ||
Financial assets, at fair value | 58 | $ 43 |
Recurring fair value measurement [member] | Marketable securities, time deposits and derivative financial instruments [member] | ||
Disclosure of fair value measurement of assets [line items] | ||
Financial assets, at fair value | 110 | 213 |
Recurring fair value measurement [member] | Marketable securities, time deposits and derivative financial instruments [member] | Debt securities | ||
Disclosure of fair value measurement of assets [line items] | ||
Financial assets, at fair value | 8 | 9 |
Recurring fair value measurement [member] | Marketable securities, time deposits and derivative financial instruments [member] | Derivative financial instruments [member] | ||
Disclosure of fair value measurement of assets [line items] | ||
Financial assets, at fair value | 102 | 204 |
Recurring fair value measurement [member] | Associated companies at fair value through profit and loss [member] | ||
Disclosure of fair value measurement of assets [line items] | ||
Financial assets, at fair value | 114 | 129 |
Recurring fair value measurement [member] | Long term financial investments [member] | ||
Disclosure of fair value measurement of assets [line items] | ||
Financial assets, at fair value | 1,974 | 2,070 |
Recurring fair value measurement [member] | Long term financial investments [member] | Fund investments [member] | ||
Disclosure of fair value measurement of assets [line items] | ||
Financial assets, at fair value | 201 | 281 |
Recurring fair value measurement [member] | Long term financial investments [member] | Available-for-sale financial investments [member] | ||
Disclosure of fair value measurement of assets [line items] | ||
Financial assets, at fair value | 1,098 | 1,182 |
Recurring fair value measurement [member] | Long term financial investments [member] | Contingent consideration receivables [member] | ||
Disclosure of fair value measurement of assets [line items] | ||
Financial assets, at fair value | 675 | 607 |
Recurring fair value measurement [member] | Level 1 of fair value hierarchy [member] | Long term financial investments [member] | ||
Disclosure of fair value measurement of assets [line items] | ||
Financial assets, at fair value | 495 | 493 |
Recurring fair value measurement [member] | Level 1 of fair value hierarchy [member] | Long term financial investments [member] | Fund investments [member] | ||
Disclosure of fair value measurement of assets [line items] | ||
Financial assets, at fair value | 7 | 20 |
Recurring fair value measurement [member] | Level 1 of fair value hierarchy [member] | Long term financial investments [member] | Available-for-sale financial investments [member] | ||
Disclosure of fair value measurement of assets [line items] | ||
Financial assets, at fair value | 488 | 473 |
Recurring fair value measurement [member] | Level 2 of fair value hierarchy [member] | Marketable securities, time deposits and derivative financial instruments [member] | ||
Disclosure of fair value measurement of assets [line items] | ||
Financial assets, at fair value | 110 | 213 |
Recurring fair value measurement [member] | Level 2 of fair value hierarchy [member] | Marketable securities, time deposits and derivative financial instruments [member] | Debt securities | ||
Disclosure of fair value measurement of assets [line items] | ||
Financial assets, at fair value | 8 | 9 |
Recurring fair value measurement [member] | Level 2 of fair value hierarchy [member] | Marketable securities, time deposits and derivative financial instruments [member] | Derivative financial instruments [member] | ||
Disclosure of fair value measurement of assets [line items] | ||
Financial assets, at fair value | 102 | 204 |
Recurring fair value measurement [member] | Level 2 of fair value hierarchy [member] | Long term financial investments [member] | ||
Disclosure of fair value measurement of assets [line items] | ||
Financial assets, at fair value | 11 | 10 |
Recurring fair value measurement [member] | Level 2 of fair value hierarchy [member] | Long term financial investments [member] | Available-for-sale financial investments [member] | ||
Disclosure of fair value measurement of assets [line items] | ||
Financial assets, at fair value | 11 | 10 |
Recurring fair value measurement [member] | Level 3 of fair value hierarchy [member] | ||
Disclosure of fair value measurement of assets [line items] | ||
Financial assets, at fair value | 58 | 43 |
Recurring fair value measurement [member] | Level 3 of fair value hierarchy [member] | Associated companies at fair value through profit and loss [member] | ||
Disclosure of fair value measurement of assets [line items] | ||
Financial assets, at fair value | 114 | 129 |
Recurring fair value measurement [member] | Level 3 of fair value hierarchy [member] | Long term financial investments [member] | ||
Disclosure of fair value measurement of assets [line items] | ||
Financial assets, at fair value | 1,468 | 1,567 |
Recurring fair value measurement [member] | Level 3 of fair value hierarchy [member] | Long term financial investments [member] | Fund investments [member] | ||
Disclosure of fair value measurement of assets [line items] | ||
Financial assets, at fair value | 194 | 261 |
Recurring fair value measurement [member] | Level 3 of fair value hierarchy [member] | Long term financial investments [member] | Available-for-sale financial investments [member] | ||
Disclosure of fair value measurement of assets [line items] | ||
Financial assets, at fair value | 599 | 699 |
Recurring fair value measurement [member] | Level 3 of fair value hierarchy [member] | Long term financial investments [member] | Contingent consideration receivables [member] | ||
Disclosure of fair value measurement of assets [line items] | ||
Financial assets, at fair value | $ 675 | $ 607 |
Financial instruments (Details
Financial instruments (Details 2) - USD ($) $ in Millions | Dec. 31, 2023 | Jun. 30, 2023 | Dec. 31, 2022 |
Disclosure of fair value measurement of liabilities [line items] | |||
Financial liabilities, at fair value | $ (20,700) | $ (20,300) | |
Recurring fair value measurement [member] | Current financial liabilities at fair value [member] | |||
Disclosure of fair value measurement of liabilities [line items] | |||
Financial liabilities, at fair value | $ (258) | (186) | |
Recurring fair value measurement [member] | Current financial liabilities at fair value [member] | Contingent consideration payables [member] | |||
Disclosure of fair value measurement of liabilities [line items] | |||
Financial liabilities, at fair value | (29) | (131) | |
Recurring fair value measurement [member] | Current financial liabilities at fair value [member] | Other financial liabilities [member] | |||
Disclosure of fair value measurement of liabilities [line items] | |||
Financial liabilities, at fair value | (189) | ||
Recurring fair value measurement [member] | Current financial liabilities at fair value [member] | Derivative financial instruments [member] | |||
Disclosure of fair value measurement of liabilities [line items] | |||
Financial liabilities, at fair value | (40) | (55) | |
Recurring fair value measurement [member] | Non-current financial liabilities at fair value [member] | |||
Disclosure of fair value measurement of liabilities [line items] | |||
Financial liabilities, at fair value | (593) | (936) | |
Recurring fair value measurement [member] | Non-current financial liabilities at fair value [member] | Other financial liabilities [member] | |||
Disclosure of fair value measurement of liabilities [line items] | |||
Financial liabilities, at fair value | (232) | ||
Recurring fair value measurement [member] | Non-current financial liabilities at fair value [member] | Non-current contingent consideration liabilities [member] | |||
Disclosure of fair value measurement of liabilities [line items] | |||
Financial liabilities, at fair value | (593) | (704) | |
Recurring fair value measurement [member] | Level 2 of fair value hierarchy [member] | Current financial liabilities at fair value [member] | |||
Disclosure of fair value measurement of liabilities [line items] | |||
Financial liabilities, at fair value | (40) | (55) | |
Recurring fair value measurement [member] | Level 2 of fair value hierarchy [member] | Current financial liabilities at fair value [member] | Derivative financial instruments [member] | |||
Disclosure of fair value measurement of liabilities [line items] | |||
Financial liabilities, at fair value | (40) | (55) | |
Recurring fair value measurement [member] | Level 3 of fair value hierarchy [member] | Current financial liabilities at fair value [member] | |||
Disclosure of fair value measurement of liabilities [line items] | |||
Financial liabilities, at fair value | (218) | (131) | |
Recurring fair value measurement [member] | Level 3 of fair value hierarchy [member] | Current financial liabilities at fair value [member] | Contingent consideration payables [member] | |||
Disclosure of fair value measurement of liabilities [line items] | |||
Financial liabilities, at fair value | (29) | (131) | |
Recurring fair value measurement [member] | Level 3 of fair value hierarchy [member] | Current financial liabilities at fair value [member] | Other financial liabilities [member] | |||
Disclosure of fair value measurement of liabilities [line items] | |||
Financial liabilities, at fair value | (189) | ||
Recurring fair value measurement [member] | Level 3 of fair value hierarchy [member] | Non-current financial liabilities at fair value [member] | |||
Disclosure of fair value measurement of liabilities [line items] | |||
Financial liabilities, at fair value | (593) | (936) | |
Recurring fair value measurement [member] | Level 3 of fair value hierarchy [member] | Non-current financial liabilities at fair value [member] | Other financial liabilities [member] | |||
Disclosure of fair value measurement of liabilities [line items] | |||
Financial liabilities, at fair value | (232) | ||
Recurring fair value measurement [member] | Level 3 of fair value hierarchy [member] | Non-current financial liabilities at fair value [member] | Non-current contingent consideration liabilities [member] | |||
Disclosure of fair value measurement of liabilities [line items] | |||
Financial liabilities, at fair value | $ (593) | $ (704) |
Financial instruments (Detail_2
Financial instruments (Details 3) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2023 | Dec. 31, 2023 | Dec. 31, 2022 | |
Disclosure of detailed information about borrowings [line items] | ||||
Transfers out of Level 3 of fair value hierarchy, assets | $ 63 | |||
Description of reasons for transfers out of Level 3 of fair value hierarchy, assets | In the first half of 2023, there were three transfers of equity securities from Level 3 to Level 1 for USD 63 million mainly due to Initial Public Offering. | |||
Financial liabilities, at fair value | $ 20,700 | $ 20,300 | ||
Financial liabilities | $ 22,500 | $ 22,300 |
Details to the consolidated s_3
Details to the consolidated statements of cash flows (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract] | ||||
Change in provisions and other non-current liabilities | $ 73 | $ 547 | $ 585 | $ 635 |
Losses/gains on disposal and other adjustments on property, plant and equipment; intangible assets;financial assets; and other non-current assets, net | 85 | (114) | (217) | (192) |
Equity-settled compensation expense | 233 | 204 | 432 | 407 |
Loss from associated companies | 2 | 3 | 2 | |
Income taxes | 452 | 347 | 898 | 797 |
Net financial expense | 149 | 186 | 264 | 367 |
Other | 36 | (8) | 29 | (8) |
Total | 2,883 | 3,061 | 5,890 | 5,414 |
Acquisition of assets (other than through business combinations) by assuming directly related liabilities | 0 | 0 | 0 | 300 |
Acquisition of assets (right of use assets) through leasing | 74 | 79 | 225 | 122 |
Property, plant and equipment | ||||
Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract] | ||||
Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss | 262 | 507 | 565 | 821 |
Right-of-use assets [member] | ||||
Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract] | ||||
Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss | 77 | 76 | 151 | 154 |
Intangible assets | ||||
Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract] | ||||
Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss | 1,486 | 1,219 | 3,105 | 2,232 |
Financial assets impaired [member] | ||||
Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract] | ||||
Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss | $ 28 | $ 97 | $ 75 | $ 199 |
Details to the consolidated s_4
Details to the consolidated statements of cash flows (Details 2) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Statement [line items] | ||||
Increase in inventories | $ (376) | $ (194) | $ (996) | $ (619) |
Increase in trade receivables | (425) | (413) | (1,275) | (909) |
Increase/(decrease) in trade payables | 127 | 11 | 214 | (132) |
Change in other current and non-current assets | (111) | 70 | (288) | (293) |
Change in other current liabilities | 623 | 472 | 679 | (112) |
Total | $ (162) | $ (54) | $ (1,666) | $ (2,065) |
Details to the consolidated s_5
Details to the consolidated statements of cash flows (Details 3) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Statement [line items] | ||||
Net cash flows | $ (84) | $ (59) | $ (123) | $ (880) |
Acquisitions | ||||
Statement [line items] | ||||
Net assets recognized as a result of acquistions of businesses | 0 | (107) | 0 | (1,086) |
Fair value of previously held equity interests | 24 | 24 | ||
Contingent consideration payables, net | 31 | (26) | 212 | |
Payments (incl. prepayments), deferred consideration and other adjustments, net | (100) | 12 | (100) | (13) |
Net cash flows | (100) | (40) | (126) | (863) |
Divestments | ||||
Statement [line items] | ||||
Net cash flows | $ 16 | (19) | $ 3 | (17) |
Non-current assets divested | 113 | 118 | ||
Current assets divested | 36 | 65 | ||
Cash and cash equivalents in subsidiary or businesses acquired or disposed | 20 | 29 | ||
Deferred sale price and other adjustments | 0 | 25 | ||
Other net cash inflows from divestments | 1 | 3 | ||
Cash outflows due to derecognized cash and cash equivalents | 20 | 20 | ||
Non-current and current liabilities divested | 43 | 43 | ||
Net identifiable assets of divested business | $ 106 | $ 140 |
Acquisition of businesses (Deta
Acquisition of businesses (Details) - USD ($) $ in Millions | Jun. 30, 2023 | Jun. 30, 2022 |
Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [line items] | ||
Property, plant and equipment | $ 13 | |
Right-of-use assets | 12 | |
Acquired research and development | 1,223 | |
Deferred tax assets | 53 | |
Trade receivables and financial and other current assets | 5 | |
Cash and cash equivalents | 89 | |
Deferred tax liabilities | (303) | |
Current and non-current lease liabilities | (12) | |
Trade payables and other liabilities | (68) | |
Net identifiable assets acquired | $ 0 | 1,012 |
Acquired cash and cash equivalents | (89) | |
Goodwill | 163 | |
Net assets recognized as a result of acquisitions of business | $ 0 | 1,086 |
Goodwill expected to be deductible for tax purposes | $ 0 |
Provisions and other non-curren
Provisions and other non-current liabilities (Details) $ in Millions | Jun. 30, 2023 USD ($) | Jun. 30, 2022 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) | Dec. 31, 2019 USD ($) | Dec. 31, 2015 USD ($) | Dec. 31, 2014 USD ($) |
Italy | Lucentis [member] | |||||||
Disclosure of other provisions [line items] | |||||||
Estimated financial effect of contingent liabilities, maximum fine | $ 125 | ||||||
Estimated financial effect of contingent liabilities, damages claimed | $ 330 | $ 1,300 | |||||
US | Exforge Group [member] | |||||||
Disclosure of other provisions [line items] | |||||||
Amount of settlement in principle | $ 245 | $ 245 | |||||
US | Sandoz [member] | |||||||
Disclosure of other provisions [line items] | |||||||
Description of nature of obligation contingent liabilities, number of states with alleged violations | 50 | ||||||
Amount of settlement in principle | $ 185 | $ 195 | |||||
France | Lucentis [member] | |||||||
Disclosure of other provisions [line items] | |||||||
Estimated financial effect of contingent liabilities, maximum fine | $ 452 |
Segmentation of key figures (De
Segmentation of key figures (Details) | 3 Months Ended | 6 Months Ended | |
Jun. 30, 2023 | Mar. 31, 2023 | Jun. 30, 2023 | |
Disclosure of operating segments [line items] | |||
Number of Reportable Segments | 2 | ||
Innovative Medicines | |||
Disclosure of operating segments [line items] | |||
Number of commercial organizational units | 2 | ||
Sandoz | |||
Disclosure of operating segments [line items] | |||
Number of Franchises | 2 | 3 |
Segmentation of key figures (_2
Segmentation of key figures (Details 2) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 13,622 | $ 12,781 | $ 26,575 | $ 25,312 |
Net sales | 13,622 | 12,781 | 26,575 | 25,312 |
Other revenues | 314 | 304 | 569 | 587 |
Cost of goods sold | (4,341) | (3,751) | (8,272) | (7,607) |
Gross profit | 9,595 | 9,334 | 18,872 | 18,292 |
Selling, general and administration | (3,686) | (3,581) | (7,129) | (7,093) |
Research and development | (2,526) | (2,498) | (5,320) | (4,818) |
Other income | 147 | 303 | 1,117 | 529 |
Other expense | (610) | (1,330) | (1,764) | (1,830) |
Operating income | $ 2,920 | $ 2,228 | $ 5,776 | $ 5,080 |
Operating income as % of net sales | 21.40% | 17.40% | 21.70% | 20.10% |
Loss from associated companies | $ (2) | $ (3) | $ (2) | |
Interest expense | (224) | $ (202) | (435) | (403) |
Other financial income and expense | 75 | 16 | 171 | 36 |
Income before taxes | 2,769 | 2,042 | 5,509 | 4,711 |
Income taxes | (452) | (347) | (898) | (797) |
Net income | 2,317 | 1,695 | 4,611 | 3,914 |
Innovative Medicines | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | 11,243 | 10,525 | 21,813 | 20,755 |
Sales to other segments | 192 | 178 | 424 | 388 |
Net sales | 11,435 | 10,703 | 22,237 | 21,143 |
Other revenues | 304 | 295 | 550 | 569 |
Cost of goods sold | (3,338) | (2,773) | (6,328) | (5,695) |
Gross profit | 8,401 | 8,225 | 16,459 | 16,017 |
Selling, general and administration | (2,955) | (2,956) | (5,715) | (5,842) |
Research and development | (2,304) | (2,302) | (4,879) | (4,414) |
Other income | 108 | 207 | 859 | 352 |
Other expense | (251) | (968) | (1,050) | (1,280) |
Operating income | $ 2,999 | $ 2,206 | $ 5,674 | $ 4,833 |
Operating income as % of net sales | 26.70% | 21% | 26% | 23.30% |
Loss from associated companies | $ 1 | $ 1 | $ 1 | |
Sandoz | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 2,379 | 2,256 | 4,762 | 4,557 |
Sales to other segments | 57 | 55 | 149 | 102 |
Net sales | 2,436 | 2,311 | 4,911 | 4,659 |
Other revenues | 6 | 7 | 12 | 13 |
Cost of goods sold | (1,250) | (1,212) | (2,517) | (2,434) |
Gross profit | 1,192 | 1,106 | 2,406 | 2,238 |
Selling, general and administration | (594) | (503) | (1,136) | (1,016) |
Research and development | (222) | (196) | (441) | (404) |
Other income | 14 | 23 | 24 | 71 |
Other expense | (178) | (73) | (322) | (138) |
Operating income | $ 212 | $ 357 | $ 531 | $ 751 |
Operating income as % of net sales | 8.90% | 15.80% | 11.20% | 16.50% |
Loss from associated companies | $ 1 | $ 1 | $ 1 | |
Corporate | ||||
Disclosure of operating segments [line items] | ||||
Sales to other segments | $ (249) | (233) | (573) | (490) |
Net sales | (249) | (233) | (573) | (490) |
Other revenues | 4 | 2 | 7 | 5 |
Cost of goods sold | 247 | 234 | 573 | 522 |
Gross profit | 2 | 3 | 7 | 37 |
Selling, general and administration | (137) | (122) | (278) | (235) |
Other income | 25 | 73 | 234 | 106 |
Other expense | (181) | (289) | (392) | (412) |
Operating income | (291) | (335) | (429) | (504) |
Loss from associated companies | $ (2) | $ (2) | $ (5) | $ (4) |
Segmentation of key figures (_3
Segmentation of key figures (Details 3) - USD ($) $ in Millions | Jun. 30, 2023 | Mar. 31, 2023 | Dec. 31, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Dec. 31, 2021 |
Disclosure of operating segments [line items] | ||||||
Total assets | $ 110,979 | $ 117,453 | ||||
Total liabilities | (59,048) | (58,030) | ||||
Total equity | 51,931 | $ 52,142 | 59,423 | $ 63,006 | $ 61,704 | $ 67,822 |
Net debt | 15,374 | 7,245 | ||||
Net operating assets | 67,305 | 66,668 | ||||
Property, plant and equipment | 10,825 | 10,764 | ||||
Goodwill | 29,522 | 29,301 | ||||
Intangible assets other than goodwill | 28,003 | 31,644 | ||||
Innovative Medicines | ||||||
Disclosure of operating segments [line items] | ||||||
Total assets | 75,633 | 75,836 | ||||
Total liabilities | (16,942) | (16,966) | ||||
Net operating assets | 58,691 | 58,870 | ||||
Property, plant and equipment | 8,463 | 8,488 | ||||
Goodwill | 21,992 | 21,857 | ||||
Intangible assets other than goodwill | 26,152 | 29,826 | ||||
Sandoz | ||||||
Disclosure of operating segments [line items] | ||||||
Total assets | 16,677 | 15,752 | ||||
Total liabilities | (4,195) | (3,710) | ||||
Net operating assets | 12,482 | 12,042 | ||||
Property, plant and equipment | 1,965 | 1,861 | ||||
Goodwill | 7,530 | 7,444 | ||||
Intangible assets other than goodwill | 1,427 | 1,460 | ||||
Corporate | ||||||
Disclosure of operating segments [line items] | ||||||
Total assets | 18,669 | 25,865 | ||||
Total liabilities | (37,911) | (37,354) | ||||
Net debt | 15,374 | 7,245 | ||||
Net operating assets | (3,868) | (4,244) | ||||
Property, plant and equipment | 397 | 415 | ||||
Intangible assets other than goodwill | $ 424 | $ 358 |
Segmentation of key figures (_4
Segmentation of key figures (Details 4) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Restructuring provision [member] | ||||
Disclosure of operating segments [line items] | ||||
Additions to restructuring provisions | $ (67) | $ (498) | $ (482) | $ (562) |
Accumulated depreciation, amortisation and impairment | ||||
Disclosure of operating segments [line items] | ||||
Impairment loss recognised in profit or loss, property, plant and equipment | (32) | (237) | (60) | (260) |
Reversal of impairment loss recognised in profit or loss, property, plant and equipment | 40 | 2 | 49 | 5 |
Impairment loss recognised in profit or loss, intangible assets and goodwill | (455) | (230) | (940) | (267) |
Impairment loss recognised in profit or loss, right of use assets | (1) | |||
Acquired research and development [member] | Accumulated depreciation, amortisation and impairment | ||||
Disclosure of operating segments [line items] | ||||
Impairment loss recognised in profit or loss, intangible assets and goodwill | (300) | |||
Currently marketed products | Accumulated depreciation, amortisation and impairment | ||||
Disclosure of operating segments [line items] | ||||
Impairment loss recognised in profit or loss, intangible assets and goodwill | (300) | (300) | ||
Innovative Medicines | Restructuring provision [member] | ||||
Disclosure of operating segments [line items] | ||||
Additions to restructuring provisions | (33) | (316) | (411) | (360) |
Innovative Medicines | Accumulated depreciation, amortisation and impairment | ||||
Disclosure of operating segments [line items] | ||||
Impairment loss recognised in profit or loss, property, plant and equipment | (31) | (236) | (58) | (258) |
Reversal of impairment loss recognised in profit or loss, property, plant and equipment | 39 | 48 | 2 | |
Impairment loss recognised in profit or loss, intangible assets and goodwill | (453) | (226) | (926) | (263) |
Sandoz | Restructuring provision [member] | ||||
Disclosure of operating segments [line items] | ||||
Additions to restructuring provisions | (11) | (20) | (16) | (30) |
Sandoz | Accumulated depreciation, amortisation and impairment | ||||
Disclosure of operating segments [line items] | ||||
Impairment loss recognised in profit or loss, property, plant and equipment | (1) | (2) | (1) | |
Reversal of impairment loss recognised in profit or loss, property, plant and equipment | 1 | 2 | 1 | 3 |
Impairment loss recognised in profit or loss, intangible assets and goodwill | (2) | (4) | (14) | (4) |
Impairment loss recognised in profit or loss, right of use assets | (1) | |||
Corporate | Restructuring provision [member] | ||||
Disclosure of operating segments [line items] | ||||
Additions to restructuring provisions | $ (23) | (162) | $ (55) | (172) |
Corporate | Accumulated depreciation, amortisation and impairment | ||||
Disclosure of operating segments [line items] | ||||
Impairment loss recognised in profit or loss, property, plant and equipment | $ (1) | $ (1) |
Segmentation of key figures (_5
Segmentation of key figures (Details 5) $ in Millions | Jun. 30, 2023 USD ($) |
Disclosure of detailed information about business combination [line items] | |
Non-current assets or disposal groups classified as held for sale | $ 1,720 |
Liabilities included in disposal groups classified as held for sale | 34 |
Innovative Medicines | Disposal groups classified as held for sale [member] | |
Disclosure of detailed information about business combination [line items] | |
Portion of consideration paid (received) consisting of cash and cash equivalents | (1,750) |
Potential milestone maximum received | 750 |
Non-current assets or disposal groups classified as held for sale | 1,720 |
Liabilities included in disposal groups classified as held for sale | $ 34 |
Segmentation of key figures (_6
Segmentation of key figures (Details 6) - Restructuring provision - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Restructuring provisions movements [roll forward] | ||||
Provision at beginning of period | $ 1,209 | $ 331 | $ 1,131 | $ 345 |
Additions | 67 | 498 | 482 | 562 |
Cash payments | (173) | (76) | (490) | (144) |
Releases | (63) | (10) | (95) | (15) |
Transfers | 1 | (1) | 0 | |
Currency translation effects | 4 | (11) | 17 | (17) |
Provision at end of period | $ 1,045 | $ 731 | $ 1,045 | $ 731 |
Segmentation of key figures (_7
Segmentation of key figures (Details 7) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 13,622 | $ 12,781 | $ 26,575 | $ 25,312 |
Net sales (in % of total net sales) | 100% | 100% | 100% | 100% |
Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 7% | 5% | ||
Net sales, change in %, cc | 9% | 8% | ||
Europe [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 4,825 | $ 4,673 | $ 9,612 | $ 9,437 |
Net sales (in % of total net sales) | 35% | 37% | 36% | 37% |
Europe [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 3% | 2% | ||
Net sales, change in %, cc | 5% | 5% | ||
US | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 4,881 | $ 4,378 | $ 9,333 | $ 8,461 |
Net sales (in % of total net sales) | 36% | 34% | 35% | 33% |
US | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 11% | 10% | ||
Net sales, change in %, cc | 11% | 10% | ||
Asia/Africa/Australasia [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 2,813 | $ 2,734 | $ 5,489 | $ 5,467 |
Net sales (in % of total net sales) | 21% | 21% | 21% | 22% |
Asia/Africa/Australasia [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 3% | 0% | ||
Net sales, change in %, cc | 9% | 8% | ||
Canada and Latin America [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 1,103 | $ 996 | $ 2,141 | $ 1,947 |
Net sales (in % of total net sales) | 8% | 8% | 8% | 8% |
Canada and Latin America [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 11% | 10% | ||
Net sales, change in %, cc | 18% | 17% | ||
Established Markets [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 9,961 | $ 9,323 | $ 19,284 | $ 18,469 |
Net sales (in % of total net sales) | 73% | 73% | 73% | 73% |
Established Markets [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 7% | 4% | ||
Net sales, change in %, cc | 7% | 6% | ||
Emerging Growth Markets [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 3,661 | $ 3,458 | $ 7,291 | $ 6,843 |
Net sales (in % of total net sales) | 27% | 27% | 27% | 27% |
Emerging Growth Markets [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 6% | 7% | ||
Net sales, change in %, cc | 15% | 15% | ||
Innovative Medicines | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 11,243 | $ 10,525 | $ 21,813 | $ 20,755 |
Net sales (in % of total net sales) | 100% | 100% | 100% | 100% |
Innovative Medicines | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 7% | 5% | ||
Net sales, change in %, cc | 9% | 8% | ||
Innovative Medicines | Europe [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 3,496 | $ 3,481 | $ 6,917 | $ 7,010 |
Net sales (in % of total net sales) | 31% | 33% | 32% | 34% |
Innovative Medicines | Europe [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 0% | (1.00%) | ||
Net sales, change in %, cc | 2% | 2% | ||
Innovative Medicines | US | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 4,503 | $ 3,967 | $ 8,575 | $ 7,642 |
Net sales (in % of total net sales) | 40% | 38% | 39% | 37% |
Innovative Medicines | US | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 14% | 12% | ||
Net sales, change in %, cc | 14% | 12% | ||
Innovative Medicines | Asia/Africa/Australasia [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 2,418 | $ 2,328 | $ 4,717 | $ 4,656 |
Net sales (in % of total net sales) | 22% | 22% | 22% | 22% |
Innovative Medicines | Asia/Africa/Australasia [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 4% | 1% | ||
Net sales, change in %, cc | 10% | 9% | ||
Innovative Medicines | Canada and Latin America [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 826 | $ 749 | $ 1,604 | $ 1,447 |
Net sales (in % of total net sales) | 7% | 7% | 7% | 7% |
Innovative Medicines | Canada and Latin America [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 10% | 11% | ||
Net sales, change in %, cc | 19% | 19% | ||
Innovative Medicines | Established Markets [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 8,276 | $ 7,742 | $ 15,954 | $ 15,314 |
Net sales (in % of total net sales) | 74% | 74% | 73% | 74% |
Innovative Medicines | Established Markets [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 7% | 4% | ||
Net sales, change in %, cc | 7% | 6% | ||
Innovative Medicines | Emerging Growth Markets [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 2,967 | $ 2,783 | $ 5,859 | $ 5,441 |
Net sales (in % of total net sales) | 26% | 26% | 27% | 26% |
Innovative Medicines | Emerging Growth Markets [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 7% | 8% | ||
Net sales, change in %, cc | 17% | 16% | ||
Sandoz | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 2,379 | $ 2,256 | $ 4,762 | $ 4,557 |
Net sales (in % of total net sales) | 100% | 100% | 100% | 100% |
Sandoz | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 5% | 4% | ||
Net sales, change in %, cc | 8% | 8% | ||
Sandoz | Europe [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 1,329 | $ 1,192 | $ 2,695 | $ 2,427 |
Net sales (in % of total net sales) | 56% | 53% | 57% | 53% |
Sandoz | Europe [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 11% | 11% | ||
Net sales, change in %, cc | 13% | 14% | ||
Sandoz | US | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 378 | $ 411 | $ 758 | $ 819 |
Net sales (in % of total net sales) | 16% | 18% | 16% | 18% |
Sandoz | US | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (8.00%) | (7.00%) | ||
Net sales, change in %, cc | (8.00%) | (7.00%) | ||
Sandoz | Asia/Africa/Australasia [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 395 | $ 406 | $ 772 | $ 811 |
Net sales (in % of total net sales) | 17% | 18% | 16% | 18% |
Sandoz | Asia/Africa/Australasia [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (3.00%) | (5.00%) | ||
Net sales, change in %, cc | 4% | 4% | ||
Sandoz | Canada and Latin America [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 277 | $ 247 | $ 537 | $ 500 |
Net sales (in % of total net sales) | 11% | 11% | 11% | 11% |
Sandoz | Canada and Latin America [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 12% | 7% | ||
Net sales, change in %, cc | 16% | 11% | ||
Sandoz | Established Markets [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 1,685 | $ 1,581 | $ 3,330 | $ 3,155 |
Net sales (in % of total net sales) | 71% | 70% | 70% | 69% |
Sandoz | Established Markets [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 7% | 6% | ||
Net sales, change in %, cc | 7% | 8% | ||
Sandoz | Emerging Growth Markets [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 694 | $ 675 | $ 1,432 | $ 1,402 |
Net sales (in % of total net sales) | 29% | 30% | 30% | 31% |
Sandoz | Emerging Growth Markets [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 3% | 2% | ||
Net sales, change in %, cc | 10% | 8% |
Segmentation of key figures (_8
Segmentation of key figures (Details 8) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 13,622 | $ 12,781 | $ 26,575 | $ 25,312 |
Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 7% | 5% | ||
Net sales, change in %, cc | 9% | 8% | ||
Innovative Medicines | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 11,243 | 10,525 | $ 21,813 | 20,755 |
Innovative Medicines | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 7% | 5% | ||
Net sales, change in %, cc | 9% | 8% | ||
Innovative Medicines | Promoted Brands [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 8,229 | 6,874 | $ 15,749 | 13,332 |
Innovative Medicines | Promoted Brands [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 20% | 18% | ||
Net sales, change in %, cc | 22% | 21% | ||
Innovative Medicines | Promoted Brands [member] | Cardiovascular [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 1,594 | 1,147 | $ 3,057 | 2,254 |
Innovative Medicines | Promoted Brands [member] | Cardiovascular [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 39% | 36% | ||
Net sales, change in %, cc | 41% | 39% | ||
Innovative Medicines | Promoted Brands [member] | Cardiovascular [member] | Entresto [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 1,516 | 1,125 | $ 2,915 | 2,218 |
Innovative Medicines | Promoted Brands [member] | Cardiovascular [member] | Entresto [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 35% | 31% | ||
Net sales, change in %, cc | 37% | 35% | ||
Innovative Medicines | Promoted Brands [member] | Cardiovascular [member] | Leqvio [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 78 | 22 | $ 142 | 36 |
Innovative Medicines | Promoted Brands [member] | Cardiovascular [member] | Leqvio [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 255% | 294% | ||
Net sales, change in %, cc | 249% | 293% | ||
Innovative Medicines | Promoted Brands [member] | Immunology [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 1,950 | 1,902 | $ 3,708 | 3,715 |
Innovative Medicines | Promoted Brands [member] | Immunology [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 3% | 0% | ||
Net sales, change in %, cc | 4% | 2% | ||
Innovative Medicines | Promoted Brands [member] | Immunology [member] | Cosentyx [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 1,272 | 1,275 | $ 2,348 | 2,434 |
Innovative Medicines | Promoted Brands [member] | Immunology [member] | Cosentyx [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 0% | (4.00%) | ||
Net sales, change in %, cc | 1% | (1.00%) | ||
Innovative Medicines | Promoted Brands [member] | Immunology [member] | Xolair [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 362 | 352 | $ 716 | 720 |
Innovative Medicines | Promoted Brands [member] | Immunology [member] | Xolair [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 3% | (1.00%) | ||
Net sales, change in %, cc | 5% | 3% | ||
Innovative Medicines | Promoted Brands [member] | Immunology [member] | Ilaris [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 316 | 275 | $ 644 | 560 |
Innovative Medicines | Promoted Brands [member] | Immunology [member] | Ilaris [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 15% | 15% | ||
Net sales, change in %, cc | 17% | 18% | ||
Innovative Medicines | Promoted Brands [member] | Immunology [member] | Other [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | 1 | |||
Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 961 | 758 | $ 1,804 | 1,450 |
Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 27% | 24% | ||
Net sales, change in %, cc | 28% | 26% | ||
Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Kesimpta [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 489 | 239 | $ 873 | 434 |
Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Kesimpta [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 105% | 101% | ||
Net sales, change in %, cc | 105% | 103% | ||
Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Zolgensma [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 311 | 379 | $ 620 | 742 |
Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Zolgensma [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (18.00%) | (16.00%) | ||
Net sales, change in %, cc | (16.00%) | (15.00%) | ||
Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Mayzent [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 94 | 85 | $ 183 | 164 |
Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Mayzent [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 11% | 12% | ||
Net sales, change in %, cc | 11% | 13% | ||
Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Aimovig [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 67 | 55 | $ 128 | 109 |
Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Aimovig [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 22% | 17% | ||
Net sales, change in %, cc | 24% | 21% | ||
Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Other [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | 1 | |||
Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 1,656 | 1,095 | $ 3,147 | 2,097 |
Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 51% | 50% | ||
Net sales, change in %, cc | 54% | 54% | ||
Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Tafinlar + Mekinist [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 496 | 452 | $ 954 | 855 |
Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Tafinlar + Mekinist [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 10% | 12% | ||
Net sales, change in %, cc | 13% | 15% | ||
Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Kisqali [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 493 | 308 | $ 908 | 547 |
Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Kisqali [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 60% | 66% | ||
Net sales, change in %, cc | 66% | 73% | ||
Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Pluvicto [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 240 | 10 | $ 451 | 12 |
Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Lutathera [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 150 | 86 | $ 299 | 211 |
Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Lutathera [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 74% | 42% | ||
Net sales, change in %, cc | 75% | 43% | ||
Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Piqray/Vijoice [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 130 | 85 | $ 246 | 158 |
Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Piqray/Vijoice [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 53% | 56% | ||
Net sales, change in %, cc | 54% | 57% | ||
Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Votrient [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 106 | 124 | $ 211 | 253 |
Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Votrient [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (15.00%) | (17.00%) | ||
Net sales, change in %, cc | (13.00%) | (15.00%) | ||
Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Tabrecta [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 41 | 30 | $ 77 | 61 |
Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Tabrecta [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 37% | 26% | ||
Net sales, change in %, cc | 37% | 27% | ||
Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Other [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 1 | |||
Innovative Medicines | Promoted Brands [member] | Hematology [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 1,782 | 1,646 | $ 3,468 | 3,184 |
Innovative Medicines | Promoted Brands [member] | Hematology [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 8% | 9% | ||
Net sales, change in %, cc | 10% | 12% | ||
Innovative Medicines | Promoted Brands [member] | Hematology [member] | Promacta/Revolade [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 583 | 534 | $ 1,130 | 1,025 |
Innovative Medicines | Promoted Brands [member] | Hematology [member] | Promacta/Revolade [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 9% | 10% | ||
Net sales, change in %, cc | 11% | 13% | ||
Innovative Medicines | Promoted Brands [member] | Hematology [member] | Tasigna [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 476 | 498 | $ 938 | 959 |
Innovative Medicines | Promoted Brands [member] | Hematology [member] | Tasigna [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (4.00%) | (2.00%) | ||
Net sales, change in %, cc | (3.00%) | 1% | ||
Innovative Medicines | Promoted Brands [member] | Hematology [member] | Jakavi [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 435 | 398 | $ 849 | 787 |
Innovative Medicines | Promoted Brands [member] | Hematology [member] | Jakavi [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 9% | 8% | ||
Net sales, change in %, cc | 11% | 12% | ||
Innovative Medicines | Promoted Brands [member] | Hematology [member] | Kymriah [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 129 | 136 | $ 264 | 263 |
Innovative Medicines | Promoted Brands [member] | Hematology [member] | Kymriah [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (5.00%) | 0% | ||
Net sales, change in %, cc | (5.00%) | 3% | ||
Innovative Medicines | Promoted Brands [member] | Hematology [member] | Scemblix [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 106 | 31 | $ 182 | 56 |
Innovative Medicines | Promoted Brands [member] | Hematology [member] | Scemblix [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 242% | 225% | ||
Net sales, change in %, cc | 248% | 228% | ||
Innovative Medicines | Promoted Brands [member] | Hematology [member] | Adakveo [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 53 | 49 | $ 105 | 93 |
Innovative Medicines | Promoted Brands [member] | Hematology [member] | Adakveo [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 8% | 13% | ||
Net sales, change in %, cc | 8% | 13% | ||
Innovative Medicines | Promoted Brands [member] | Hematology [member] | Other [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | 1 | |||
Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 286 | 326 | $ 565 | 632 |
Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (12.00%) | (11.00%) | ||
Net sales, change in %, cc | (11.00%) | (8.00%) | ||
Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | Ultibro Group [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 114 | 126 | $ 228 | 258 |
Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | Ultibro Group [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (10.00%) | (12.00%) | ||
Net sales, change in %, cc | (8.00%) | (8.00%) | ||
Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | Xiidra [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 96 | 126 | $ 185 | 233 |
Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | Xiidra [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (24.00%) | (21.00%) | ||
Net sales, change in %, cc | (24.00%) | (21.00%) | ||
Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | Beovu [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 53 | 54 | $ 104 | 102 |
Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | Beovu [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (2.00%) | 2% | ||
Net sales, change in %, cc | 0% | 5% | ||
Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | Other Respiratory [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 23 | 20 | $ 48 | 39 |
Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | Other Respiratory [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 15% | 23% | ||
Net sales, change in %, cc | 22% | 31% | ||
Innovative Medicines | Established Brands [member] | Established Brands [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 3,014 | 3,651 | $ 6,064 | 7,423 |
Innovative Medicines | Established Brands [member] | Established Brands [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (17.00%) | (18.00%) | ||
Net sales, change in %, cc | (13.00%) | (14.00%) | ||
Innovative Medicines | Established Brands [member] | Established Brands [member] | Lucentis [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 395 | 501 | $ 811 | 1,021 |
Innovative Medicines | Established Brands [member] | Established Brands [member] | Lucentis [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (21.00%) | (21.00%) | ||
Net sales, change in %, cc | (20.00%) | (17.00%) | ||
Innovative Medicines | Established Brands [member] | Established Brands [member] | Sandostatin [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 331 | 318 | $ 660 | 638 |
Innovative Medicines | Established Brands [member] | Established Brands [member] | Sandostatin [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 4% | 3% | ||
Net sales, change in %, cc | 5% | 5% | ||
Innovative Medicines | Established Brands [member] | Established Brands [member] | Gilenya [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 269 | 555 | $ 501 | 1,160 |
Innovative Medicines | Established Brands [member] | Established Brands [member] | Gilenya [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (52.00%) | (57.00%) | ||
Net sales, change in %, cc | (52.00%) | (56.00%) | ||
Innovative Medicines | Established Brands [member] | Established Brands [member] | Exforge Group [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 184 | 199 | $ 370 | 399 |
Innovative Medicines | Established Brands [member] | Established Brands [member] | Exforge Group [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (8.00%) | (7.00%) | ||
Net sales, change in %, cc | (4.00%) | (3.00%) | ||
Innovative Medicines | Established Brands [member] | Established Brands [member] | Galvus Group [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 175 | 222 | $ 358 | 438 |
Innovative Medicines | Established Brands [member] | Established Brands [member] | Galvus Group [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (21.00%) | (18.00%) | ||
Net sales, change in %, cc | (15.00%) | (12.00%) | ||
Innovative Medicines | Established Brands [member] | Established Brands [member] | Diovan Group [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 155 | 159 | $ 313 | 350 |
Innovative Medicines | Established Brands [member] | Established Brands [member] | Diovan Group [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (3.00%) | (11.00%) | ||
Net sales, change in %, cc | 2% | (5.00%) | ||
Innovative Medicines | Established Brands [member] | Established Brands [member] | Gleevec/Glivec [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 142 | 194 | $ 289 | 392 |
Innovative Medicines | Established Brands [member] | Established Brands [member] | Gleevec/Glivec [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (27.00%) | (26.00%) | ||
Net sales, change in %, cc | (24.00%) | (23.00%) | ||
Innovative Medicines | Established Brands [member] | Established Brands [member] | Afinitor/Votubia [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 116 | 143 | $ 226 | 281 |
Innovative Medicines | Established Brands [member] | Established Brands [member] | Afinitor/Votubia [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (19.00%) | (20.00%) | ||
Net sales, change in %, cc | (17.00%) | (17.00%) | ||
Innovative Medicines | Established Brands [member] | Established Brands [member] | Contract manufacturing [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 132 | 83 | $ 255 | 182 |
Innovative Medicines | Established Brands [member] | Established Brands [member] | Contract manufacturing [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 59% | 40% | ||
Net sales, change in %, cc | 56% | 41% | ||
Innovative Medicines | Established Brands [member] | Established Brands [member] | Other [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 1,115 | $ 1,277 | $ 2,281 | $ 2,562 |
Innovative Medicines | Established Brands [member] | Established Brands [member] | Other [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (13.00%) | (11.00%) | ||
Net sales, change in %, cc | (5.00%) | (4.00%) |
Segmentation of key figures (_9
Segmentation of key figures (Details 9) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 13,622 | $ 12,781 | $ 26,575 | $ 25,312 |
Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 7% | 5% | ||
Net sales, change in %, cc | 9% | 8% | ||
US | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 4,881 | 4,378 | $ 9,333 | 8,461 |
US | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 11% | 10% | ||
Net sales, change in %, cc | 11% | 10% | ||
Innovative Medicines | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 11,243 | 10,525 | $ 21,813 | 20,755 |
Innovative Medicines | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 7% | 5% | ||
Net sales, change in %, cc | 9% | 8% | ||
Innovative Medicines | Promoted Brands [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 8,229 | 6,874 | $ 15,749 | 13,332 |
Innovative Medicines | Promoted Brands [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 20% | 18% | ||
Net sales, change in %, cc | 22% | 21% | ||
Innovative Medicines | Promoted Brands [member] | Cardiovascular [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 1,594 | 1,147 | $ 3,057 | 2,254 |
Innovative Medicines | Promoted Brands [member] | Cardiovascular [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 39% | 36% | ||
Net sales, change in %, cc | 41% | 39% | ||
Innovative Medicines | Promoted Brands [member] | Immunology [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 1,950 | 1,902 | $ 3,708 | 3,715 |
Innovative Medicines | Promoted Brands [member] | Immunology [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 3% | 0% | ||
Net sales, change in %, cc | 4% | 2% | ||
Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 961 | 758 | $ 1,804 | 1,450 |
Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 27% | 24% | ||
Net sales, change in %, cc | 28% | 26% | ||
Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 1,656 | 1,095 | $ 3,147 | 2,097 |
Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 51% | 50% | ||
Net sales, change in %, cc | 54% | 54% | ||
Innovative Medicines | Promoted Brands [member] | Hematology [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 1,782 | 1,646 | $ 3,468 | 3,184 |
Innovative Medicines | Promoted Brands [member] | Hematology [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 8% | 9% | ||
Net sales, change in %, cc | 10% | 12% | ||
Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 286 | 326 | $ 565 | 632 |
Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (12.00%) | (11.00%) | ||
Net sales, change in %, cc | (11.00%) | (8.00%) | ||
Innovative Medicines | Established Brands [member] | Established Brands [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 3,014 | 3,651 | $ 6,064 | 7,423 |
Innovative Medicines | Established Brands [member] | Established Brands [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (17.00%) | (18.00%) | ||
Net sales, change in %, cc | (13.00%) | (14.00%) | ||
Innovative Medicines | US | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 4,503 | 3,967 | $ 8,575 | 7,642 |
Innovative Medicines | US | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 14% | 12% | ||
Net sales, change in %, cc | 14% | 12% | ||
Innovative Medicines | Rest of the world [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 6,740 | $ 13,238 | ||
Innovative Medicines | Rest of the world [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 3% | 1% | ||
Net sales, change in %, cc | 7% | 6% | ||
Innovative Medicines | Entresto [member] | Promoted Brands [member] | Cardiovascular [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 1,516 | 1,125 | $ 2,915 | 2,218 |
Innovative Medicines | Entresto [member] | Promoted Brands [member] | Cardiovascular [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 35% | 31% | ||
Net sales, change in %, cc | 37% | 35% | ||
Innovative Medicines | Cosentyx [member] | Promoted Brands [member] | Immunology [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 1,272 | 1,275 | $ 2,348 | 2,434 |
Innovative Medicines | Cosentyx [member] | Promoted Brands [member] | Immunology [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 0% | (4.00%) | ||
Net sales, change in %, cc | 1% | (1.00%) | ||
Innovative Medicines | Promacta/Revolade [member] | Promoted Brands [member] | Hematology [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 583 | 534 | $ 1,130 | 1,025 |
Innovative Medicines | Promacta/Revolade [member] | Promoted Brands [member] | Hematology [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 9% | 10% | ||
Net sales, change in %, cc | 11% | 13% | ||
Innovative Medicines | Tafinlar + Mekinist [member] | Promoted Brands [member] | Solid Tumors [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 496 | 452 | $ 954 | 855 |
Innovative Medicines | Tafinlar + Mekinist [member] | Promoted Brands [member] | Solid Tumors [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 10% | 12% | ||
Net sales, change in %, cc | 13% | 15% | ||
Innovative Medicines | Tasigna [member] | Promoted Brands [member] | Hematology [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 476 | 498 | $ 938 | 959 |
Innovative Medicines | Tasigna [member] | Promoted Brands [member] | Hematology [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (4.00%) | (2.00%) | ||
Net sales, change in %, cc | (3.00%) | 1% | ||
Innovative Medicines | Kisqali [member] | Promoted Brands [member] | Solid Tumors [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 493 | 308 | $ 908 | 547 |
Innovative Medicines | Kisqali [member] | Promoted Brands [member] | Solid Tumors [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 60% | 66% | ||
Net sales, change in %, cc | 66% | 73% | ||
Innovative Medicines | Kesimpta [member] | Promoted Brands [member] | Neuroscience [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 489 | 239 | $ 873 | 434 |
Innovative Medicines | Kesimpta [member] | Promoted Brands [member] | Neuroscience [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 105% | 101% | ||
Net sales, change in %, cc | 105% | 103% | ||
Innovative Medicines | Jakavi [member] | Promoted Brands [member] | Hematology [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 435 | 398 | $ 849 | 787 |
Innovative Medicines | Jakavi [member] | Promoted Brands [member] | Hematology [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 9% | 8% | ||
Net sales, change in %, cc | 11% | 12% | ||
Innovative Medicines | Lucentis [member] | Established Brands [member] | Established Brands [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 395 | 501 | $ 811 | 1,021 |
Innovative Medicines | Lucentis [member] | Established Brands [member] | Established Brands [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (21.00%) | (21.00%) | ||
Net sales, change in %, cc | (20.00%) | (17.00%) | ||
Innovative Medicines | Xolair [member] | Promoted Brands [member] | Immunology [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 362 | 352 | $ 716 | 720 |
Innovative Medicines | Xolair [member] | Promoted Brands [member] | Immunology [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 3% | (1.00%) | ||
Net sales, change in %, cc | 5% | 3% | ||
Innovative Medicines | Sandostatin [member] | Established Brands [member] | Established Brands [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 331 | 318 | $ 660 | 638 |
Innovative Medicines | Sandostatin [member] | Established Brands [member] | Established Brands [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 4% | 3% | ||
Net sales, change in %, cc | 5% | 5% | ||
Innovative Medicines | Ilaris [member] | Promoted Brands [member] | Immunology [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 316 | 275 | $ 644 | 560 |
Innovative Medicines | Ilaris [member] | Promoted Brands [member] | Immunology [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 15% | 15% | ||
Net sales, change in %, cc | 17% | 18% | ||
Innovative Medicines | Zolgensma [member] | Promoted Brands [member] | Neuroscience [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 311 | 379 | $ 620 | 742 |
Innovative Medicines | Zolgensma [member] | Promoted Brands [member] | Neuroscience [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (18.00%) | (16.00%) | ||
Net sales, change in %, cc | (16.00%) | (15.00%) | ||
Innovative Medicines | Gilenya [member] | Established Brands [member] | Established Brands [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 269 | 555 | $ 501 | 1,160 |
Innovative Medicines | Gilenya [member] | Established Brands [member] | Established Brands [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (52.00%) | (57.00%) | ||
Net sales, change in %, cc | (52.00%) | (56.00%) | ||
Innovative Medicines | Pluvicto [member] | Promoted Brands [member] | Solid Tumors [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 240 | 10 | $ 451 | 12 |
Innovative Medicines | Exforge Group [member] | Established Brands [member] | Established Brands [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 184 | 199 | $ 370 | 399 |
Innovative Medicines | Exforge Group [member] | Established Brands [member] | Established Brands [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (8.00%) | (7.00%) | ||
Net sales, change in %, cc | (4.00%) | (3.00%) | ||
Innovative Medicines | Galvus Group [member] | Established Brands [member] | Established Brands [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 175 | 222 | $ 358 | 438 |
Innovative Medicines | Galvus Group [member] | Established Brands [member] | Established Brands [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (21.00%) | (18.00%) | ||
Net sales, change in %, cc | (15.00%) | (12.00%) | ||
Innovative Medicines | Diovan Group [member] | Established Brands [member] | Established Brands [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 155 | 159 | $ 313 | 350 |
Innovative Medicines | Diovan Group [member] | Established Brands [member] | Established Brands [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (3.00%) | (11.00%) | ||
Net sales, change in %, cc | 2% | (5.00%) | ||
Innovative Medicines | Lutathera [member] | Promoted Brands [member] | Solid Tumors [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 150 | 86 | $ 299 | 211 |
Innovative Medicines | Lutathera [member] | Promoted Brands [member] | Solid Tumors [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 74% | 42% | ||
Net sales, change in %, cc | 75% | 43% | ||
Innovative Medicines | Gleevec/Glivec [member] | Established Brands [member] | Established Brands [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 142 | $ 194 | $ 289 | $ 392 |
Innovative Medicines | Gleevec/Glivec [member] | Established Brands [member] | Established Brands [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (27.00%) | (26.00%) | ||
Net sales, change in %, cc | (24.00%) | (23.00%) | ||
Innovative Medicines | Top 20 products [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 8,790 | $ 16,947 | ||
Innovative Medicines | Top 20 products [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 9% | 7% | ||
Net sales, change in %, cc | 11% | 10% | ||
Innovative Medicines | Top 20 products [member] | US | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 3,685 | $ 6,981 | ||
Innovative Medicines | Top 20 products [member] | US | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 15% | 14% | ||
Innovative Medicines | Top 20 products [member] | Rest of the world [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 5,105 | $ 9,966 | ||
Innovative Medicines | Top 20 products [member] | Rest of the world [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 4% | 2% | ||
Net sales, change in %, cc | 8% | 7% | ||
Innovative Medicines | Top 20 products [member] | Entresto [member] | Promoted Brands [member] | Cardiovascular [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 1,516 | $ 2,915 | ||
Innovative Medicines | Top 20 products [member] | Entresto [member] | Promoted Brands [member] | Cardiovascular [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 35% | 31% | ||
Net sales, change in %, cc | 37% | 35% | ||
Innovative Medicines | Top 20 products [member] | Entresto [member] | US | Promoted Brands [member] | Cardiovascular [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 755 | $ 1,459 | ||
Innovative Medicines | Top 20 products [member] | Entresto [member] | US | Promoted Brands [member] | Cardiovascular [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 38% | 34% | ||
Innovative Medicines | Top 20 products [member] | Entresto [member] | Rest of the world [member] | Promoted Brands [member] | Cardiovascular [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 761 | $ 1,456 | ||
Innovative Medicines | Top 20 products [member] | Entresto [member] | Rest of the world [member] | Promoted Brands [member] | Cardiovascular [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 32% | 29% | ||
Net sales, change in %, cc | 36% | 35% | ||
Innovative Medicines | Top 20 products [member] | Cosentyx [member] | Promoted Brands [member] | Immunology [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 1,272 | $ 2,348 | ||
Innovative Medicines | Top 20 products [member] | Cosentyx [member] | Promoted Brands [member] | Immunology [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 0% | (4.00%) | ||
Net sales, change in %, cc | 1% | (1.00%) | ||
Innovative Medicines | Top 20 products [member] | Cosentyx [member] | US | Promoted Brands [member] | Immunology [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 650 | $ 1,178 | ||
Innovative Medicines | Top 20 products [member] | Cosentyx [member] | US | Promoted Brands [member] | Immunology [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (12.00%) | (16.00%) | ||
Innovative Medicines | Top 20 products [member] | Cosentyx [member] | Rest of the world [member] | Promoted Brands [member] | Immunology [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 622 | $ 1,170 | ||
Innovative Medicines | Top 20 products [member] | Cosentyx [member] | Rest of the world [member] | Promoted Brands [member] | Immunology [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 15% | 13% | ||
Net sales, change in %, cc | 18% | 18% | ||
Innovative Medicines | Top 20 products [member] | Promacta/Revolade [member] | Promoted Brands [member] | Hematology [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 583 | $ 1,130 | ||
Innovative Medicines | Top 20 products [member] | Promacta/Revolade [member] | Promoted Brands [member] | Hematology [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 9% | 10% | ||
Net sales, change in %, cc | 11% | 13% | ||
Innovative Medicines | Top 20 products [member] | Promacta/Revolade [member] | US | Promoted Brands [member] | Hematology [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 313 | $ 590 | ||
Innovative Medicines | Top 20 products [member] | Promacta/Revolade [member] | US | Promoted Brands [member] | Hematology [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 16% | 14% | ||
Innovative Medicines | Top 20 products [member] | Promacta/Revolade [member] | Rest of the world [member] | Promoted Brands [member] | Hematology [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 270 | $ 540 | ||
Innovative Medicines | Top 20 products [member] | Promacta/Revolade [member] | Rest of the world [member] | Promoted Brands [member] | Hematology [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 2% | 6% | ||
Net sales, change in %, cc | 5% | 11% | ||
Innovative Medicines | Top 20 products [member] | Tafinlar + Mekinist [member] | Promoted Brands [member] | Solid Tumors [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 496 | $ 954 | ||
Innovative Medicines | Top 20 products [member] | Tafinlar + Mekinist [member] | Promoted Brands [member] | Solid Tumors [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 10% | 12% | ||
Net sales, change in %, cc | 13% | 15% | ||
Innovative Medicines | Top 20 products [member] | Tafinlar + Mekinist [member] | US | Promoted Brands [member] | Solid Tumors [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 196 | $ 390 | ||
Innovative Medicines | Top 20 products [member] | Tafinlar + Mekinist [member] | US | Promoted Brands [member] | Solid Tumors [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 13% | 19% | ||
Innovative Medicines | Top 20 products [member] | Tafinlar + Mekinist [member] | Rest of the world [member] | Promoted Brands [member] | Solid Tumors [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 300 | $ 564 | ||
Innovative Medicines | Top 20 products [member] | Tafinlar + Mekinist [member] | Rest of the world [member] | Promoted Brands [member] | Solid Tumors [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 8% | 7% | ||
Net sales, change in %, cc | 12% | 13% | ||
Innovative Medicines | Top 20 products [member] | Tasigna [member] | Promoted Brands [member] | Hematology [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 476 | $ 938 | ||
Innovative Medicines | Top 20 products [member] | Tasigna [member] | Promoted Brands [member] | Hematology [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (4.00%) | (2.00%) | ||
Net sales, change in %, cc | (3.00%) | 1% | ||
Innovative Medicines | Top 20 products [member] | Tasigna [member] | US | Promoted Brands [member] | Hematology [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 232 | $ 443 | ||
Innovative Medicines | Top 20 products [member] | Tasigna [member] | US | Promoted Brands [member] | Hematology [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 6% | 5% | ||
Innovative Medicines | Top 20 products [member] | Tasigna [member] | Rest of the world [member] | Promoted Brands [member] | Hematology [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 244 | $ 495 | ||
Innovative Medicines | Top 20 products [member] | Tasigna [member] | Rest of the world [member] | Promoted Brands [member] | Hematology [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (13.00%) | (8.00%) | ||
Net sales, change in %, cc | (10.00%) | (3.00%) | ||
Innovative Medicines | Top 20 products [member] | Kisqali [member] | Promoted Brands [member] | Solid Tumors [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 493 | $ 908 | ||
Innovative Medicines | Top 20 products [member] | Kisqali [member] | Promoted Brands [member] | Solid Tumors [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 60% | 66% | ||
Net sales, change in %, cc | 66% | 73% | ||
Innovative Medicines | Top 20 products [member] | Kisqali [member] | US | Promoted Brands [member] | Solid Tumors [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 224 | $ 406 | ||
Innovative Medicines | Top 20 products [member] | Kisqali [member] | US | Promoted Brands [member] | Solid Tumors [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 104% | 115% | ||
Innovative Medicines | Top 20 products [member] | Kisqali [member] | Rest of the world [member] | Promoted Brands [member] | Solid Tumors [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 269 | $ 502 | ||
Innovative Medicines | Top 20 products [member] | Kisqali [member] | Rest of the world [member] | Promoted Brands [member] | Solid Tumors [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 36% | 40% | ||
Net sales, change in %, cc | 45% | 50% | ||
Innovative Medicines | Top 20 products [member] | Kesimpta [member] | Promoted Brands [member] | Neuroscience [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 489 | $ 873 | ||
Innovative Medicines | Top 20 products [member] | Kesimpta [member] | Promoted Brands [member] | Neuroscience [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 105% | 101% | ||
Net sales, change in %, cc | 105% | 103% | ||
Innovative Medicines | Top 20 products [member] | Kesimpta [member] | US | Promoted Brands [member] | Neuroscience [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 373 | $ 668 | ||
Innovative Medicines | Top 20 products [member] | Kesimpta [member] | US | Promoted Brands [member] | Neuroscience [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 83% | 78% | ||
Innovative Medicines | Top 20 products [member] | Kesimpta [member] | Rest of the world [member] | Promoted Brands [member] | Neuroscience [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 116 | $ 205 | ||
Innovative Medicines | Top 20 products [member] | Kesimpta [member] | Rest of the world [member] | Promoted Brands [member] | Neuroscience [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 231% | 253% | ||
Net sales, change in %, cc | 226% | 261% | ||
Innovative Medicines | Top 20 products [member] | Jakavi [member] | Promoted Brands [member] | Hematology [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 435 | $ 849 | ||
Innovative Medicines | Top 20 products [member] | Jakavi [member] | Promoted Brands [member] | Hematology [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 9% | 8% | ||
Net sales, change in %, cc | 11% | 12% | ||
Innovative Medicines | Top 20 products [member] | Jakavi [member] | Rest of the world [member] | Promoted Brands [member] | Hematology [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 435 | $ 849 | ||
Innovative Medicines | Top 20 products [member] | Jakavi [member] | Rest of the world [member] | Promoted Brands [member] | Hematology [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 9% | 8% | ||
Net sales, change in %, cc | 11% | 12% | ||
Innovative Medicines | Top 20 products [member] | Lucentis [member] | Established Brands [member] | Established Brands [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 395 | $ 811 | ||
Innovative Medicines | Top 20 products [member] | Lucentis [member] | Established Brands [member] | Established Brands [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (21.00%) | (21.00%) | ||
Net sales, change in %, cc | (20.00%) | (17.00%) | ||
Innovative Medicines | Top 20 products [member] | Lucentis [member] | Rest of the world [member] | Established Brands [member] | Established Brands [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 395 | $ 811 | ||
Innovative Medicines | Top 20 products [member] | Lucentis [member] | Rest of the world [member] | Established Brands [member] | Established Brands [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (21.00%) | (21.00%) | ||
Net sales, change in %, cc | (20.00%) | (17.00%) | ||
Innovative Medicines | Top 20 products [member] | Xolair [member] | Promoted Brands [member] | Immunology [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 362 | $ 716 | ||
Innovative Medicines | Top 20 products [member] | Xolair [member] | Promoted Brands [member] | Immunology [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 3% | (1.00%) | ||
Net sales, change in %, cc | 5% | 3% | ||
Innovative Medicines | Top 20 products [member] | Xolair [member] | Rest of the world [member] | Promoted Brands [member] | Immunology [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 362 | $ 716 | ||
Innovative Medicines | Top 20 products [member] | Xolair [member] | Rest of the world [member] | Promoted Brands [member] | Immunology [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 3% | (1.00%) | ||
Net sales, change in %, cc | 5% | 3% | ||
Innovative Medicines | Top 20 products [member] | Sandostatin [member] | Established Brands [member] | Established Brands [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 331 | $ 660 | ||
Innovative Medicines | Top 20 products [member] | Sandostatin [member] | Established Brands [member] | Established Brands [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 4% | 3% | ||
Net sales, change in %, cc | 5% | 5% | ||
Innovative Medicines | Top 20 products [member] | Sandostatin [member] | US | Established Brands [member] | Established Brands [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 203 | $ 412 | ||
Innovative Medicines | Top 20 products [member] | Sandostatin [member] | US | Established Brands [member] | Established Brands [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (2.00%) | 1% | ||
Innovative Medicines | Top 20 products [member] | Sandostatin [member] | Rest of the world [member] | Established Brands [member] | Established Brands [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 128 | $ 248 | ||
Innovative Medicines | Top 20 products [member] | Sandostatin [member] | Rest of the world [member] | Established Brands [member] | Established Brands [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 15% | 7% | ||
Net sales, change in %, cc | 18% | 12% | ||
Innovative Medicines | Top 20 products [member] | Ilaris [member] | Promoted Brands [member] | Immunology [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 316 | $ 644 | ||
Innovative Medicines | Top 20 products [member] | Ilaris [member] | Promoted Brands [member] | Immunology [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 15% | 15% | ||
Net sales, change in %, cc | 17% | 18% | ||
Innovative Medicines | Top 20 products [member] | Ilaris [member] | US | Promoted Brands [member] | Immunology [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 163 | $ 304 | ||
Innovative Medicines | Top 20 products [member] | Ilaris [member] | US | Promoted Brands [member] | Immunology [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 20% | 16% | ||
Innovative Medicines | Top 20 products [member] | Ilaris [member] | Rest of the world [member] | Promoted Brands [member] | Immunology [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 153 | $ 340 | ||
Innovative Medicines | Top 20 products [member] | Ilaris [member] | Rest of the world [member] | Promoted Brands [member] | Immunology [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 10% | 14% | ||
Net sales, change in %, cc | 13% | 19% | ||
Innovative Medicines | Top 20 products [member] | Zolgensma [member] | Promoted Brands [member] | Neuroscience [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 311 | $ 620 | ||
Innovative Medicines | Top 20 products [member] | Zolgensma [member] | Promoted Brands [member] | Neuroscience [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (18.00%) | (16.00%) | ||
Net sales, change in %, cc | (16.00%) | (15.00%) | ||
Innovative Medicines | Top 20 products [member] | Zolgensma [member] | US | Promoted Brands [member] | Neuroscience [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 84 | $ 193 | ||
Innovative Medicines | Top 20 products [member] | Zolgensma [member] | US | Promoted Brands [member] | Neuroscience [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (32.00%) | (18.00%) | ||
Innovative Medicines | Top 20 products [member] | Zolgensma [member] | Rest of the world [member] | Promoted Brands [member] | Neuroscience [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 227 | $ 427 | ||
Innovative Medicines | Top 20 products [member] | Zolgensma [member] | Rest of the world [member] | Promoted Brands [member] | Neuroscience [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (11.00%) | (16.00%) | ||
Net sales, change in %, cc | (9.00%) | (14.00%) | ||
Innovative Medicines | Top 20 products [member] | Gilenya [member] | Established Brands [member] | Established Brands [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 269 | $ 501 | ||
Innovative Medicines | Top 20 products [member] | Gilenya [member] | Established Brands [member] | Established Brands [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (52.00%) | (57.00%) | ||
Net sales, change in %, cc | (52.00%) | (56.00%) | ||
Innovative Medicines | Top 20 products [member] | Gilenya [member] | US | Established Brands [member] | Established Brands [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 104 | $ 184 | ||
Innovative Medicines | Top 20 products [member] | Gilenya [member] | US | Established Brands [member] | Established Brands [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (69.00%) | (71.00%) | ||
Innovative Medicines | Top 20 products [member] | Gilenya [member] | Rest of the world [member] | Established Brands [member] | Established Brands [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 165 | $ 317 | ||
Innovative Medicines | Top 20 products [member] | Gilenya [member] | Rest of the world [member] | Established Brands [member] | Established Brands [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (26.00%) | (39.00%) | ||
Net sales, change in %, cc | (26.00%) | (37.00%) | ||
Innovative Medicines | Top 20 products [member] | Pluvicto [member] | Promoted Brands [member] | Solid Tumors [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 240 | $ 451 | ||
Innovative Medicines | Top 20 products [member] | Pluvicto [member] | US | Promoted Brands [member] | Solid Tumors [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | 227 | 432 | ||
Innovative Medicines | Top 20 products [member] | Pluvicto [member] | Rest of the world [member] | Promoted Brands [member] | Solid Tumors [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | 13 | 19 | ||
Innovative Medicines | Top 20 products [member] | Exforge Group [member] | Established Brands [member] | Established Brands [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 184 | $ 370 | ||
Innovative Medicines | Top 20 products [member] | Exforge Group [member] | Established Brands [member] | Established Brands [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (8.00%) | (7.00%) | ||
Net sales, change in %, cc | (4.00%) | (3.00%) | ||
Innovative Medicines | Top 20 products [member] | Exforge Group [member] | US | Established Brands [member] | Established Brands [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 4 | $ 8 | ||
Innovative Medicines | Top 20 products [member] | Exforge Group [member] | US | Established Brands [member] | Established Brands [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 33% | 14% | ||
Innovative Medicines | Top 20 products [member] | Exforge Group [member] | Rest of the world [member] | Established Brands [member] | Established Brands [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 180 | $ 362 | ||
Innovative Medicines | Top 20 products [member] | Exforge Group [member] | Rest of the world [member] | Established Brands [member] | Established Brands [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (8.00%) | (8.00%) | ||
Net sales, change in %, cc | (4.00%) | (3.00%) | ||
Innovative Medicines | Top 20 products [member] | Galvus Group [member] | Established Brands [member] | Established Brands [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 175 | $ 358 | ||
Innovative Medicines | Top 20 products [member] | Galvus Group [member] | Established Brands [member] | Established Brands [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (21.00%) | (18.00%) | ||
Net sales, change in %, cc | (15.00%) | (12.00%) | ||
Innovative Medicines | Top 20 products [member] | Galvus Group [member] | Rest of the world [member] | Established Brands [member] | Established Brands [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 175 | $ 358 | ||
Innovative Medicines | Top 20 products [member] | Galvus Group [member] | Rest of the world [member] | Established Brands [member] | Established Brands [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (21.00%) | (18.00%) | ||
Net sales, change in %, cc | (15.00%) | (12.00%) | ||
Innovative Medicines | Top 20 products [member] | Diovan Group [member] | Established Brands [member] | Established Brands [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 155 | $ 313 | ||
Innovative Medicines | Top 20 products [member] | Diovan Group [member] | Established Brands [member] | Established Brands [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (3.00%) | (11.00%) | ||
Net sales, change in %, cc | 2% | (5.00%) | ||
Innovative Medicines | Top 20 products [member] | Diovan Group [member] | US | Established Brands [member] | Established Brands [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 12 | $ 27 | ||
Innovative Medicines | Top 20 products [member] | Diovan Group [member] | US | Established Brands [member] | Established Brands [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (14.00%) | 0% | ||
Innovative Medicines | Top 20 products [member] | Diovan Group [member] | Rest of the world [member] | Established Brands [member] | Established Brands [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 143 | $ 286 | ||
Innovative Medicines | Top 20 products [member] | Diovan Group [member] | Rest of the world [member] | Established Brands [member] | Established Brands [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (1.00%) | (11.00%) | ||
Net sales, change in %, cc | 4% | (5.00%) | ||
Innovative Medicines | Top 20 products [member] | Lutathera [member] | Promoted Brands [member] | Solid Tumors [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 150 | $ 299 | ||
Innovative Medicines | Top 20 products [member] | Lutathera [member] | Promoted Brands [member] | Solid Tumors [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 74% | 42% | ||
Net sales, change in %, cc | 75% | 43% | ||
Innovative Medicines | Top 20 products [member] | Lutathera [member] | US | Promoted Brands [member] | Solid Tumors [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 106 | $ 210 | ||
Innovative Medicines | Top 20 products [member] | Lutathera [member] | US | Promoted Brands [member] | Solid Tumors [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 108% | 48% | ||
Innovative Medicines | Top 20 products [member] | Lutathera [member] | Rest of the world [member] | Promoted Brands [member] | Solid Tumors [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 44 | $ 89 | ||
Innovative Medicines | Top 20 products [member] | Lutathera [member] | Rest of the world [member] | Promoted Brands [member] | Solid Tumors [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 26% | 29% | ||
Net sales, change in %, cc | 28% | 35% | ||
Innovative Medicines | Top 20 products [member] | Gleevec/Glivec [member] | Established Brands [member] | Established Brands [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 142 | $ 289 | ||
Innovative Medicines | Top 20 products [member] | Gleevec/Glivec [member] | Established Brands [member] | Established Brands [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (27.00%) | (26.00%) | ||
Net sales, change in %, cc | (24.00%) | (23.00%) | ||
Innovative Medicines | Top 20 products [member] | Gleevec/Glivec [member] | US | Established Brands [member] | Established Brands [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 39 | $ 77 | ||
Innovative Medicines | Top 20 products [member] | Gleevec/Glivec [member] | US | Established Brands [member] | Established Brands [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (32.00%) | (28.00%) | ||
Innovative Medicines | Top 20 products [member] | Gleevec/Glivec [member] | Rest of the world [member] | Established Brands [member] | Established Brands [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 103 | $ 212 | ||
Innovative Medicines | Top 20 products [member] | Gleevec/Glivec [member] | Rest of the world [member] | Established Brands [member] | Established Brands [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (25.00%) | (26.00%) | ||
Net sales, change in %, cc | (21.00%) | (21.00%) | ||
Innovative Medicines | Rest of portfolio [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 2,453 | $ 4,866 | ||
Innovative Medicines | Rest of portfolio [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 0% | 0% | ||
Net sales, change in %, cc | 5% | 5% | ||
Innovative Medicines | Rest of portfolio [member] | US | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 818 | $ 1,594 | ||
Innovative Medicines | Rest of portfolio [member] | US | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 5% | 7% | ||
Innovative Medicines | Rest of portfolio [member] | Rest of the world [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 1,635 | $ 3,272 | ||
Innovative Medicines | Rest of portfolio [member] | Rest of the world [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | (2.00%) | (3.00%) | ||
Net sales, change in %, cc | 5% | 4% |
Segmentation of key figures _10
Segmentation of key figures (Details 10) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 13,622 | $ 12,781 | $ 26,575 | $ 25,312 |
Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 7% | 5% | ||
Net sales, change in %, cc | 9% | 8% | ||
Sandoz | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 2,379 | 2,256 | $ 4,762 | 4,557 |
Sandoz | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 5% | 4% | ||
Net sales, change in %, cc | 8% | 8% | ||
Sandoz | Generics [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 1,848 | 1,783 | $ 3,713 | 3,619 |
Sandoz | Generics [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 4% | 3% | ||
Net sales, change in %, cc | 6% | 6% | ||
Sandoz | Biosimilars [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales to third parties | $ 531 | $ 473 | $ 1,049 | $ 938 |
Sandoz | Biosimilars [member] | Change over period [member] | ||||
Disclosure of operating segments [line items] | ||||
Net sales, change in % | 12% | 12% | ||
Net sales, change in %, cc | 13% | 15% |
Segmentation of key figures _11
Segmentation of key figures (Details 11) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Disclosure of operating segments [line items] | ||||
Profit sharing income | $ 246 | $ 223 | $ 445 | $ 428 |
Royalty income | 23 | 9 | 49 | 20 |
Milestone income | 25 | 21 | 28 | 40 |
Other | 20 | 51 | 47 | 99 |
Other revenues | 314 | 304 | 569 | 587 |
Innovative Medicines | ||||
Disclosure of operating segments [line items] | ||||
Profit sharing income | 246 | 223 | 445 | 428 |
Royalty income | 19 | 3 | 41 | 6 |
Milestone income | 25 | 20 | 28 | 39 |
Other | 14 | 49 | 36 | 96 |
Other revenues | 304 | 295 | 550 | 569 |
Sandoz | ||||
Disclosure of operating segments [line items] | ||||
Royalty income | 4 | 4 | 8 | 9 |
Milestone income | 1 | 1 | ||
Other | 2 | 2 | 4 | 3 |
Other revenues | 6 | 7 | 12 | 13 |
Corporate | ||||
Disclosure of operating segments [line items] | ||||
Royalty income | 2 | 5 | ||
Other | 4 | 7 | ||
Other revenues | $ 4 | $ 2 | $ 7 | $ 5 |